Aneurysmal Bone Cyst

MONDO:0018815 Pathograph 18 Show in embeddings browser bone neoplasm

A locally aggressive, blood-filled, expansile bone lesion of children and young adults, reclassified in the last two decades from a reactive process to a true neoplasm. The reclassification rests on a specific and unusual genetic mechanism: a translocation places the entire intact USP6 coding sequence downstream of a strong constitutive promoter, most often that of the osteoblast cadherin CDH11. No fusion protein is made. What changes is transcription, and overexpressed USP6 then drives NF-kappa-B activation, matrix metalloproteinase production, osteolysis and the florid vascularity that gives the lesion its name. Roughly 70% of cases carry the rearrangement; the remaining 30% are ABC-like change arising within a different neoplasm and are a separate entity that this pathograph does not describe.

Ask OpenScientist

Ask a research question about Aneurysmal Bone Cyst. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
3
Histopath.
5
Phenotypes
18
Pathograph
3
Genes
4
Medical Actions
3
Subtypes
11
References
1
Deep Research
◆

Subtypes

3
Primary (USP6-rearranged)
The true neoplasm. Carries a USP6 rearrangement, which is what the pathograph in this entry describes.
Show evidence (1 reference)
PMID:30553465 SUPPORT Human Clinical
"Aneurysmal bone cyst (ABC) is a benign but locally aggressive, mostly pediatric neoplasm, with characteristic USP6 gene rearrangement that distinguishes it from a secondary ABC and other primary bone tumors."
States that the USP6 rearrangement is what defines this subtype against the secondary form.
Secondary (ABC-like change, USP6-negative)
Not a distinct tumour at all but a reactive cystic change occurring inside another neoplasm, most often giant cell tumour of bone, chondroblastoma, fibrous dysplasia or osteosarcoma. It is USP6-negative, and its behaviour and treatment follow the underlying lesion, not this entry.
Show evidence (1 reference)
PMID:31611201 SUPPORT Human Clinical
"All secondary ABC, GCT and TOS were negative."
Establishes that the secondary form does not carry the rearrangement, which is the basis for separating it from the primary lesion.
Solid variant
A rare form lacking the characteristic cystic blood-filled spaces while retaining the neoplastic nature of the primary lesion.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"The solid variant of ABC is also considered a true neoplasm but is rare."
States the existence and neoplastic status of the solid variant.
⚙

Pathophysiology

7
USP6 Promoter-Swap Rearrangement
The initiating lesion, and an unusual one. The recurrent t(16;17)(q22;p13) juxtaposes the CDH11 promoter region to the entire USP6 coding sequence, so the protein made is ordinary USP6 and only its transcription is deregulated. That distinguishes this from the fusion-protein oncogenes it superficially resembles. At least thirteen partner promoters are now known, all of them strongly expressed in bone or connective tissue, which is consistent with the promoter being the operative element rather than the partner gene.
USP6 hgnc:12629 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves USP6 (hgnc:12629). hgnc:12629 is a gene from the HUGO Gene Nomenclature Committee. CDH11 hgnc:1750 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CDH11 (hgnc:1750). hgnc:1750 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
USP6 Overexpression with Intact Deubiquitinase Activity The rearrangement raises USP6 transcription; the protein itself is unaltered.
Show evidence (3 references)
PMID:15026324 SUPPORT Human Clinical
"Herein we show that a recurring ABC chromosomal translocation t(16;17)(q22;p13) creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence on 17p13."
Describes the promoter-to-intact-coding-sequence architecture that defines this node.
PMID:15026324 SUPPORT Human Clinical
"CDH11 is expressed strongly in bone, and our findings implicate a novel oncogenic mechanism in which deregulated USP6 transcription results from juxtaposition to the highly active CDH11 promoter."
States explicitly that the mechanism is transcriptional deregulation by a strong promoter, which is the point of this node.
PMID:30553465 SUPPORT Human Clinical
"Including our case, the list of currently known USP6 fusion partners in primary ABC include: CDH11, CNBP, COL1A1, CTNNB1, EIF1, FOSL2, OMD, PAFAH1B1, RUNX2, SEC31A, SPARC, STAT3 and THRAP3."
Enumerates the thirteen partners, whose only shared property is strong expression, which is the evidence that the promoter rather than the partner is what matters.
USP6 Overexpression with Intact Deubiquitinase Activity
Overexpressed USP6 is sufficient on its own to initiate tumour formation. The domain mapping is informative: the deubiquitinase activity is required, while the TBC domain that binds the Arf6 GTPase is not. That narrows the mechanism to the protease function rather than to vesicular trafficking, which had been the other candidate.
protein deubiquitination GO:0016579 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein deubiquitination (GO:0016579). GO:0016579 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
RANKL-Driven Osteoclast Recruitment The neoplastic spindle cells express high levels of RANKL, which recruits and activates the osteoclast-like giant cells. The steps between USP6 overexpression and RANKL induction are not established, so the edge is graded accordingly.
NF-kappa-B Activation USP6 activates NF-kappa-B, mediated in part by the GTPase RhoA and its effector kinase ROCK.
Show evidence (2 references)
PMID:20418905 SUPPORT In Vitro
"In this study we show that TRE17 is sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6."
Establishes that the deubiquitinase activity is the required function and rules out the Arf6-binding route.
PMID:15509545 SUPPORT Human Clinical
"USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were not found in multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts."
Identifies the myofibroblastic spindle cell as the neoplastic cell and, by exclusion, establishes that the giant cells, endothelium and osteoblasts of the lesion are recruited rather than transformed. This is why the downstream nodes are framed as recruitment and reaction rather than as clonal expansion.
NF-kappa-B Activation
Canonical NF-kappa-B signalling is switched on downstream of USP6, and is the transcriptional route to the matrix proteases that do the tissue damage.
canonical NF-kappaB signal transduction GO:0007249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased canonical NF-kappaB signal transduction (GO:0007249). GO:0007249 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Matrix Metalloproteinase Production and Matrix Degradation NF-kappa-B drives transcription of MMP-9, with MMP-10 also induced.
Show evidence (1 reference)
PMID:20418905 SUPPORT In Vitro
"TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK."
Places NF-kappa-B between the oncogene and the protease output.
Matrix Metalloproteinase Production and Matrix Degradation
MMP-9 and MMP-10 are induced and degrade the surrounding matrix. Matrix proteases are the common requirement of the three processes that define this lesion histologically: osteolysis, inflammatory cell recruitment and extensive new vessel formation.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
extracellular matrix disassembly GO:0022617 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix disassembly (GO:0022617). GO:0022617 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Osteolysis and Vascular Space Formation Matrix degradation permits bone destruction and the ingrowth of the thin-walled blood-filled spaces that give the lesion its name and its imaging appearance.
Show evidence (1 reference)
PMID:20418905 SUPPORT In Vitro
"ABCs are characterized by osteolysis, inflammatory recruitment and extensive vascularization, the processes in which matrix proteases have a prominent role."
States the link between matrix proteases and the three defining processes of the lesion.
RANKL-Driven Osteoclast Recruitment
The neoplastic stromal and myofibroblastic cells express high levels of RANKL, while the osteoclast-like multinucleated giant cells they recruit express RANK. RANKL binding to RANK stimulates those osteoclasts, and this is the arm of the lesion that denosumab targets. It is not specific to this tumour, which is why the same drug works in giant cell tumour of bone and chondroblastoma.
multinucleated giant cell CL:0000647 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves multinucleated giant cell (CL:0000647). CL:0000647 is a cell type from the Cell Ontology. osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
TNFSF11 hgnc:11926 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TNFSF11 (hgnc:11926). hgnc:11926 is a gene from the HUGO Gene Nomenclature Committee. TNFRSF11A hgnc:11908 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TNFRSF11A (hgnc:11908). hgnc:11908 is a gene from the HUGO Gene Nomenclature Committee.
osteoclast differentiation GO:0030316 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased osteoclast differentiation (GO:0030316). GO:0030316 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Osteolysis and Vascular Space Formation RANK-stimulated osteoclasts resorb bone, producing the lytic component of the lesion.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"RANKL is a tumor necrosis factor that stimulates osteoclasts by binding to RANK. This mechanism is not unique to ABC as it can also occur in other tumors, such as giant cell tumor and chondroblastoma, which explains in part the lytic component seen in these lesions"
States the RANKL-RANK mechanism and is explicit that it is shared with other giant-cell-rich tumours rather than being specific to this one.
Osteolysis and Vascular Space Formation
The lesion proper: an expansile, lytic, blood-filled cavity with septated spaces, produced by osteoclast-mediated bone resorption alongside florid angiogenesis. The fluid-fluid levels seen on cross-sectional imaging are the direct radiological signature of these spaces.
osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
bone resorption GO:0045453 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased bone resorption (GO:0045453). GO:0045453 is a biological process from the Gene Ontology. ↑ INCREASED angiogenesis GO:0001525 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased angiogenesis (GO:0001525). GO:0001525 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Aneurysmal Bone Cyst The expansile lytic lesion is the structural phenotype itself.
Local Bone Destruction and Mass Effect Progressive destruction of cortex and expansion into surrounding tissue produce the clinical consequences.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"The imaging appearance of ABC is variable; however, a lytic and expansile lesion with fluid-fluid levels is the most common presentation."
Describes the lytic expansile blood-filled lesion that constitutes this node.
Local Bone Destruction and Mass Effect
The clinical endpoint. The lesion does not metastasise, so morbidity is entirely local and depends on site: pain and pathological fracture in long bones, cord compression in the spine, proptosis and threatened sight in the orbit.
Downstream
Pathologic Fracture Cortical destruction weakens the bone enough to fracture under normal load, in about 15% of cases.
Bone Pain Expansion and cortical destruction produce local bone pain, the usual presenting symptom.
Spinal Cord Compression A spinal lesion expanding into the canal compresses the cord, which is the indication for the most aggressive management.
Proptosis An orbital lesion displaces the globe forward and can threaten sight.
Show evidence (1 reference)
PMID:36356178 SUPPORT Human Clinical
"Presentations are varied and can include pain, proptosis, decreased vision, and extraocular motility disturbance."
Illustrates how the same lesion produces entirely site-determined morbidity.
✶

Histopathology

3
Blood-Filled Cystic Spaces Without Endothelial Lining
The defining microscopic appearance: blood-filled cystic spaces separated by cellular septa, lacking any epithelial or endothelial lining. The absence of a lining is what distinguishes these from true vascular spaces and is why the lesion is neither an aneurysm nor a cyst despite its name.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"Microscopically, ABC is characterized by solid areas and blood-filled cystic spaces that lack an epithelial or endothelial lining, separated by cellular septa."
Describes the architecture and the absent lining that define this finding.
Osteoclast-Like Multinucleated Giant Cells
Giant cells expressing RANK, alongside the neoplastic stromal and myofibroblastic cells that express RANKL. These are recruited rather than transformed: the USP6 rearrangement is confined to the spindle cells.
Show evidence (2 references)
PMID:35941207 SUPPORT Human Clinical
"a cellular component that includes osteoclast-like multinucleated giant cells that express high levels of receptor activator of nuclear kappa B (RANK) and neoplastic stromal mononuclear and myo/fibroblastic cells that express high levels of RANK ligand (RANKL)"
Describes the two cell populations and their receptor-ligand relationship.
PMID:15509545 SUPPORT Human Clinical
"USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were not found in multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts."
Establishes that the giant cells do not carry the driving lesion, which is why they are described here as recruited.
Absence of Cytologic Atypia
Mitoses are usually conspicuous, but cytologic atypia should not be present and necrosis is uncommon. This is the histological line between this lesion and telangiectatic osteosarcoma, its principal mimic.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"Mitoses are usually conspicuous; however, cytologic atypia should not be present and necrosis is uncommon."
States the negative features that separate this lesion from its malignant mimic.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Aneurysmal Bone Cyst Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Eye 1
Proptosis HP:0000520 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proptosis (HP:0000520). HP:0000520 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36356178 SUPPORT Human Clinical
"Presentations are varied and can include pain, proptosis, decreased vision, and extraocular motility disturbance."
Names proptosis among the presenting features of orbital disease.
Musculoskeletal 2
Aneurysmal Bone Cyst HP:0012063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aneurysmal bone cyst (HP:0012063). HP:0012063 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"The imaging appearance of ABC is variable; however, a lytic and expansile lesion with fluid-fluid levels is the most common presentation."
Describes the lesion and its characteristic imaging appearance.
Pathologic Fracture OCCASIONAL HP:0002756 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pathologic fracture (HP:0002756). HP:0002756 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"Pathological fracture occurs more commonly in telangiectatic osteosarcoma (30%) compared to ABC (15%) due to relatively rapid tumor growth and extensive bone destruction"
Gives the 15% rate, which supports both the phenotype and the OCCASIONAL band, and contrasts it with the mimic.
Nervous System 1
Spinal Cord Compression HP:0002176 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spinal cord compression (HP:0002176). HP:0002176 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31476792 SUPPORT Human Clinical
"SAE is used as a pre-operative procedure to reduce intra-operative bleeding in the case of large lesions and as primary treatment for spinal lesions."
Establishes spinal involvement as a distinct management problem, which is why the neurological consequence is recorded separately.
Constitutional 1
Bone Pain HP:0002653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone pain (HP:0002653). HP:0002653 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34754635 SUPPORT Human Clinical
"There was an improvement in the VAS score, and clinically, there was a significant reduction in pain and swelling."
Pain and swelling are the clinical endpoints tracked in this lesion.
🧬

Genetic Associations

3
USP6 (Promoter-Swap Rearrangement with Intact Coding Sequence)
Gene: USP6 hgnc:12629 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is USP6 (hgnc:12629). hgnc:12629 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (4 references)
PMID:15026324 SUPPORT Human Clinical
"CDH11 is expressed strongly in bone, and our findings implicate a novel oncogenic mechanism in which deregulated USP6 transcription results from juxtaposition to the highly active CDH11 promoter."
States the promoter-swap mechanism that this block records.
PMID:15026324 SUPPORT Human Clinical
"ABC was regarded historically as a nonneoplastic process, but recent cytogenetic data have shown clonal rearrangements of chromosomal bands 16q22 and 17p13, indicating a neoplastic basis in at least some ABCs."
Records the clonality evidence that reclassified this lesion as a neoplasm.
PMID:30553465 SUPPORT Human Clinical
"Including our case, the list of currently known USP6 fusion partners in primary ABC include: CDH11, CNBP, COL1A1, CTNNB1, EIF1, FOSL2, OMD, PAFAH1B1, RUNX2, SEC31A, SPARC, STAT3 and THRAP3."
Enumerates the known partner promoters.
+ 1 more reference
CDH11 (Commonest Partner Promoter)
Gene: CDH11 hgnc:1750 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CDH11 (hgnc:1750). hgnc:1750 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: COOPERATING variant_origin: SOMATIC
Show evidence (1 reference)
PMID:15026324 SUPPORT Human Clinical
"Herein we show that a recurring ABC chromosomal translocation t(16;17)(q22;p13) creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence on 17p13."
Identifies CDH11 as contributing the promoter region only.
COL1A1 (Alternative Partner Promoter)
Gene: COL1A1 hgnc:2197 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COL1A1 (hgnc:2197). hgnc:2197 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: COOPERATING variant_origin: SOMATIC
Show evidence (1 reference)
PMID:26142538 SUPPORT Human Clinical
"This diagnosis was supported by cytogenetic analysis revealing a t(17;17)(p13;q21) translocation corresponding to the USP6 and COL1A1 loci."
Documents COL1A1 as an alternative partner locus in the soft-tissue form.
💊

Medical Actions

4
Curettage with Local Adjuvants and Bone Grafting
Action: curettage procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is curettage procedure (NCIT:C15216). NCIT:C15216 is a clinical intervention from the NCI Thesaurus. Ontology label: Curettage Procedure NCIT:C15216
Platform: Surgery
The standard operation: manual and high-speed burr curettage, local adjuvants such as phenol, liquid nitrogen or argon laser, and grafting to fill the defect. Recurrence after treatment is high, which is what drives interest in the alternatives below.
Mechanism Target:
INHIBITS Osteolysis and Vascular Space Formation — Physically removes the lesional tissue and its vascular spaces, without addressing the driver in any cells left behind.
Show evidence (1 reference)
PMID:31476792 SUPPORT Human Clinical
"Standard treatment consists of curettage (manual + motorized high-speed burr) plus local adjuvants and bone grafting to fill the void."
Describes the operation and its components.
Show evidence (2 references)
PMID:31476792 SUPPORT Human Clinical
"It can have an unpredictable behavior, with a high recurrence rate after treatment. Treatment is based on personal and institutional experience and preferences."
Records both the high recurrence rate and, candidly, that management is driven by local preference rather than by trial evidence.
PMID:35941207 SUPPORT Human Clinical
"The authors found a local recurrence/persistent disease rate requiring further treatment in 44.1% of the group treated by intralesional excision."
Quantifies recurrence after intralesional curettage in a direct comparison against sclerotherapy and en bloc resection.
Percutaneous Sclerotherapy
Action: sclerotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is sclerotherapy (NCIT:C62732). NCIT:C62732 is a clinical intervention from the NCI Thesaurus. Ontology label: Sclerotherapy NCIT:C62732
Agent: polidocanol CHEBI:46859 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses polidocanol (CHEBI:46859). CHEBI:46859 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Intralesional injection of a sclerosant, most often polidocanol, under fluoroscopic guidance. Useful where surgical access is difficult or would endanger nearby structures. In a single-centre series of 26 patients, ossification was complete in 92% and 70% were pain-free at three months.
Mechanism Target:
INHIBITS Osteolysis and Vascular Space Formation — Sclerosis obliterates the vascular spaces, after which the cavity ossifies.
Show evidence (1 reference)
PMID:34754635 SUPPORT Human Clinical
"Ossification was complete in 24 (92.3%) patients and partial in two (7.7%) patients."
Ossification of the cavity is the direct radiological readout that the vascular spaces have been obliterated.
Show evidence (3 references)
PMID:34754635 SUPPORT Human Clinical
"Eighteen patients (70%) were pain-free at the end of three months."
Gives the symptomatic response rate at three months.
PMID:34754635 SUPPORT Human Clinical
"Sclerotherapy provides an effective, minimally invasive treatment for ABC and is particularly useful for deep lesions, challenging access for surgery and potentially damaging vital structures."
States the niche in which this option is preferred over surgery.
PMID:35941207 REFUTE Human Clinical
"In the sclerotherapy group, persistent disease was seen in 90.6% of cases. Even though a complete cure was achieved in only 9.4% of cases with serial sclerotherapy, adequate healing with reduction in lesion volume was achieved in 71.9% of cases."
Argues against reading the single-centre ossification figure as cure. In a comparative series 90.6% had persistent disease and only 9.4% were cured, though 71.9% achieved adequate healing. The two sources are not in conflict so much as measuring different endpoints, and both are recorded.
Denosumab
Action: monoclonal antibody therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is monoclonal antibody therapy (NCIT:C15490). NCIT:C15490 is a clinical intervention from the NCI Thesaurus. Ontology label: Monoclonal Antibody Therapy NCIT:C15490
Agent: denosumab NCIT:C61313 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses denosumab (NCIT:C61313). NCIT:C61313 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
An anti-RANKL monoclonal antibody, borrowed from giant cell tumour of bone on the strength of histological similarity rather than shared genetics. Pain relief and neurological improvement are rapid, and most patients ossify. The case against routine use is equally clear: recurrence in 18.6%, mostly in adults, and five of forty-three reported patients required intensive care for hypercalcaemia.
Mechanism Target:
INHIBITS RANKL-Driven Osteoclast Recruitment — Denosumab binds RANKL and prevents it engaging RANK on the giant cells, which is the node this drug acts on directly. It does not touch the USP6 driver upstream, which is the likely reason lesions recur when it is stopped.
Show evidence (1 reference)
PMID:34481945 SUPPORT Human Clinical
"Radiological assessment showed ossification and/or volume reduction in 36/39 patients."
Ossification and volume reduction are the direct readouts of suppressed resorption at this node.
Show evidence (3 references)
PMID:34481945 SUPPORT Human Clinical
"Pain relief and neurological improvement were rapid and sustained."
Gives the symptomatic benefit.
PMID:34481945 SUPPORT Human Clinical
"Eight patients (18,6%) presented a recurrence after or during denosumab therapy of whom 7 were adults. Adverse events occurred in 11 patients, 5 of them were admitted to the intensive care unit due to hypercalcemia."
Records the recurrence rate and the serious toxicity, which together are why this is reserved for advanced disease.
PMID:34481945 REFUTE Human Clinical
"The oncological outcome remains unclear with a recurrence rate of 18,6% during/after denosumab therapy, mostly in adults."
Regraded from NO_EVIDENCE on review. The quote does bear on the claim - it argues against durable disease control, rather than being silent on it - so REFUTE against an efficacy claim is the correct axis.
Selective Arterial Embolization
Action: embolization therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is embolization therapy (NCIT:C15230). NCIT:C15230 is a clinical intervention from the NCI Thesaurus. Ontology label: Embolization Therapy NCIT:C15230
Platform: Device
Used pre-operatively to reduce bleeding from large lesions, and as primary treatment for spinal lesions where surgery is hazardous.
Mechanism Target:
INHIBITS Osteolysis and Vascular Space Formation — Occludes the feeding vessels supplying the vascular spaces of the lesion.
Show evidence (1 reference)
PMID:31476792 SUPPORT Human Clinical
"SAE is used as a pre-operative procedure to reduce intra-operative bleeding in the case of large lesions and as primary treatment for spinal lesions."
The reduction in operative bleeding is direct evidence that the procedure acts on the vascular supply of this node.
Show evidence (1 reference)
PMID:31476792 SUPPORT Human Clinical
"In anatomical locations that are difficult to reach surgically, percutaneous procedures (injection of sclerosant agents, radiofrequency thermal ablation (RFTA)) or selective arterial embolization (SAE) are used."
States the setting in which this and the other percutaneous options are chosen.
🔬

Diagnosis

3
USP6 break-apart fluorescence in situ hybridization (PRESENT)
A break-apart FISH probe for USP6 separates primary aneurysmal bone cyst from the secondary form, giant cell tumour of bone and telangiectatic osteosarcoma, which are morphologically similar. Read the operating characteristics carefully: in the validation study specificity and positive predictive value were both 100%, but sensitivity was only 53% and negative predictive value 69%. A positive result settles the diagnosis; a negative result does not exclude it. Note also that this 53% falls short of the 70 to 75% rearrangement rate the same paper cites from the literature, so some of the shortfall is assay performance rather than true absence of the rearrangement.
Show evidence (2 references)
PMID:31611201 SUPPORT Human Clinical
"The test sensitivity and specificity in primary ABC were 53% (9/17) and 100% (18/18), respectively. The positive predictive value and negative predictive value were 100% (9/9) and 69% (18/26), respectively."
Gives the operating characteristics that make a positive result decisive and a negative result uninformative.
PMID:31611201 SUPPORT Human Clinical
"Ubiquitin specific protease 6 (USP6) gene rearrangement has been reported in approximately 70%-75% of aneurysmal bone cyst cases."
The literature rearrangement rate against which the 53% assay sensitivity should be read.
Magnetic resonance imaging (PRESENT)
Radiographs first, then MRI or less often CT for characterisation. The typical appearance is a lytic expansile lesion with fluid-fluid levels.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"As with any bone tumor, the initial evaluation of ABCs should be done with radiographs followed by magnetic resonance imaging or less frequently computed tomography for further characterization."
States the imaging sequence used for evaluation.
Diagnostic biopsy before treatment (PRESENT)
Biopsy is recommended before treatment because telangiectatic osteosarcoma, a malignant tumour, can look identical on imaging. This is the single most consequential pitfall in managing the lesion, since the treatments below would be badly wrong for an osteosarcoma.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"The main differential diagnosis of an ABC in the pediatric population is unicameral bone cyst (UBC) and telangiectatic osteosarcoma, therefore a biopsy is recommended before treatment."
States the differential and the resulting recommendation for pre-treatment biopsy.
📊

Prevalence

2
Worldwide
Point Prevalence 0.32 per 100,000 1–9 per 1,000,000
Reported prevalence 0.32 per 100,000; annual incidence 0.14 per 100,000; approximately 1% of all bone tumours.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"ABC accounts for approximately 1% of all bone tumors with a reported incidence of 0.14 per 100,000 individuals and a prevalence of 0.32 cases per 100,000 individuals"
Gives incidence, prevalence and the share of all bone tumours.
Worldwide
Annual Incidence 0.14 per 100,000 1–9 per 1,000,000 per year
Annual incidence 0.14 per 100,000 individuals.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"ABC accounts for approximately 1% of all bone tumors with a reported incidence of 0.14 per 100,000 individuals and a prevalence of 0.32 cases per 100,000 individuals"
Same source sentence, recorded separately because incidence and prevalence are distinct measures.
🌍

Epidemiology

2
Age distribution
Predominantly a lesion of the first two decades of life, and the reason it was long grouped with the reactive lesions of growing bone.
Show evidence (1 reference)
PMID:15026324 SUPPORT Human Clinical
"Aneurysmal bone cyst (ABC) is a locally aggressive osseous lesion that typically occurs during the first two decades of life."
Gives the age distribution and the locally aggressive behaviour.
Primary versus secondary proportion
About 70% of lesions called aneurysmal bone cyst are true neoplasms carrying the USP6 rearrangement. The remaining 30% are ABC-like change in some other bone neoplasm, which look the same down a microscope and behave according to the lesion underneath.
Show evidence (1 reference)
PMID:35941207 SUPPORT Human Clinical
"ABC, which accounts for approximately 70% of the cases, is now recognized to be a true neoplasm, whereas ABC-like changes associated to other bone neoplasms (also referred in the literature as secondary ABC) accounts for the remaining 30%."
Gives the split between the true neoplasm and the ABC-like change, and states the neoplastic reclassification.
{ }

Source YAML

click to show 
name: Aneurysmal Bone Cyst
creation_date: '2026-09-03T15:00:00Z'
description: >-
  A locally aggressive, blood-filled, expansile bone lesion of children and young
  adults, reclassified in the last two decades from a reactive process to a true
  neoplasm. The reclassification rests on a specific and unusual genetic
  mechanism: a translocation places the entire intact USP6 coding sequence
  downstream of a strong constitutive promoter, most often that of the osteoblast
  cadherin CDH11. No fusion protein is made. What changes is transcription, and
  overexpressed USP6 then drives NF-kappa-B activation, matrix metalloproteinase
  production, osteolysis and the florid vascularity that gives the lesion its
  name. Roughly 70% of cases carry the rearrangement; the remaining 30% are
  ABC-like change arising within a different neoplasm and are a separate entity
  that this pathograph does not describe.
categories:
- Bone Neoplasm
- Locally Aggressive Non-Metastasising Neoplasm
- Promoter-Swap Fusion Neoplasm
parents:
- bone neoplasm
synonyms:
- ABC
- aneurysmal cyst of bone
epidemiology:
- name: Age distribution
  description: >-
    Predominantly a lesion of the first two decades of life, and the reason it was
    long grouped with the reactive lesions of growing bone.
  evidence:
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Aneurysmal bone cyst (ABC) is a locally aggressive osseous lesion that typically
      occurs during the first two decades of life.
    explanation: Gives the age distribution and the locally aggressive behaviour.
- name: Primary versus secondary proportion
  description: >-
    About 70% of lesions called aneurysmal bone cyst are true neoplasms carrying
    the USP6 rearrangement. The remaining 30% are ABC-like change in some other
    bone neoplasm, which look the same down a microscope and behave according to
    the lesion underneath.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'ABC, which accounts for approximately 70% of the cases, is now recognized to be
      a true neoplasm, whereas ABC-like changes associated to other bone neoplasms (also referred
      in the literature as secondary ABC) accounts for the remaining 30%.'
    explanation: Gives the split between the true neoplasm and the ABC-like change, and states
      the neoplastic reclassification.
has_subtypes:
- name: Primary
  display_name: Primary (USP6-rearranged)
  description: >-
    The true neoplasm. Carries a USP6 rearrangement, which is what the pathograph
    in this entry describes.
  evidence:
  - reference: PMID:30553465
    reference_title: Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation
      sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Aneurysmal bone cyst (ABC) is a benign but locally aggressive, mostly pediatric
      neoplasm, with characteristic USP6 gene rearrangement that distinguishes it from a secondary
      ABC and other primary bone tumors.'
    explanation: States that the USP6 rearrangement is what defines this subtype against the
      secondary form.
- name: Secondary
  display_name: Secondary (ABC-like change, USP6-negative)
  description: >-
    Not a distinct tumour at all but a reactive cystic change occurring inside
    another neoplasm, most often giant cell tumour of bone, chondroblastoma,
    fibrous dysplasia or osteosarcoma. It is USP6-negative, and its behaviour and
    treatment follow the underlying lesion, not this entry.
  evidence:
  - reference: PMID:31611201
    reference_title: Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for
      Diagnosis of Primary Aneurysmal Bone Cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All secondary ABC, GCT and TOS were negative.
    explanation: Establishes that the secondary form does not carry the rearrangement, which is
      the basis for separating it from the primary lesion.
- name: Solid variant
  description: >-
    A rare form lacking the characteristic cystic blood-filled spaces while
    retaining the neoplastic nature of the primary lesion.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The solid variant of ABC is also considered a true neoplasm but is rare.
    explanation: States the existence and neoplastic status of the solid variant.
pathophysiology:
- name: USP6 Promoter-Swap Rearrangement
  biological_scale: MOLECULAR
  subtypes:
  - Primary
  description: >-
    The initiating lesion, and an unusual one. The recurrent t(16;17)(q22;p13)
    juxtaposes the CDH11 promoter region to the entire USP6 coding sequence, so
    the protein made is ordinary USP6 and only its transcription is deregulated.
    That distinguishes this from the fusion-protein oncogenes it superficially
    resembles. At least thirteen partner promoters are now known, all of them
    strongly expressed in bone or connective tissue, which is consistent with the
    promoter being the operative element rather than the partner gene.
  genes:
  - preferred_term: USP6
    term:
      id: hgnc:12629
      label: USP6
  - preferred_term: CDH11
    term:
      id: hgnc:1750
      label: CDH11
  evidence:
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Herein we show that a recurring ABC chromosomal translocation t(16;17)(q22;p13)
      creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region
      on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence
      on 17p13.'
    explanation: Describes the promoter-to-intact-coding-sequence architecture that defines this
      node.
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'CDH11 is expressed strongly in bone, and our findings implicate a novel oncogenic
      mechanism in which deregulated USP6 transcription results from juxtaposition to the highly
      active CDH11 promoter.'
    explanation: States explicitly that the mechanism is transcriptional deregulation by a strong
      promoter, which is the point of this node.
  - reference: PMID:30553465
    reference_title: Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation
      sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Including our case, the list of currently known USP6 fusion partners in primary
      ABC include: CDH11, CNBP, COL1A1, CTNNB1, EIF1, FOSL2, OMD, PAFAH1B1, RUNX2, SEC31A, SPARC,
      STAT3 and THRAP3.'
    explanation: Enumerates the thirteen partners, whose only shared property is strong
      expression, which is the evidence that the promoter rather than the partner is what
      matters.
  downstream:
  - target: USP6 Overexpression with Intact Deubiquitinase Activity
    causal_link_type: DIRECT
    description: The rearrangement raises USP6 transcription; the protein itself is unaltered.
    evidence:
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Recent work revealed that ABCs harbor translocation of TRE17/USP6, leading to its
        transcriptional upregulation.
      explanation: States that the consequence of the translocation is transcriptional
        upregulation, which is exactly what this edge asserts.
- name: USP6 Overexpression with Intact Deubiquitinase Activity
  biological_scale: MOLECULAR
  description: >-
    Overexpressed USP6 is sufficient on its own to initiate tumour formation. The
    domain mapping is informative: the deubiquitinase activity is required, while
    the TBC domain that binds the Arf6 GTPase is not. That narrows the mechanism
    to the protease function rather than to vesicular trafficking, which had been
    the other candidate.
  biological_processes:
  - preferred_term: protein deubiquitination
    modifier: INCREASED
    term:
      id: GO:0016579
      label: protein deubiquitination
  evidence:
  - reference: PMID:20418905
    reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
      production via activation of NF-kappaB.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: 'In this study we show that TRE17 is sufficient to induce expression of MMP-9 and
      MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6.'
    explanation: Establishes that the deubiquitinase activity is the required function and rules
      out the Arf6-binding route.
  - reference: PMID:15509545
    reference_title: USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts
      and are absent in so-called secondary aneurysmal bone cysts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were
      not found in multinucleated giant cells, inflammatory cells, endothelial cells, or
      osteoblasts.'
    explanation: Identifies the myofibroblastic spindle cell as the neoplastic cell and, by
      exclusion, establishes that the giant cells, endothelium and osteoblasts of the lesion are
      recruited rather than transformed. This is why the downstream nodes are framed as
      recruitment and reaction rather than as clonal expansion.
  downstream:
  - target: RANKL-Driven Osteoclast Recruitment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The neoplastic spindle cells express high levels of RANKL, which recruits and
      activates the osteoclast-like giant cells. The steps between USP6 overexpression and RANKL
      induction are not established, so the edge is graded accordingly.
    evidence:
    - reference: PMID:35941207
      reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'a cellular component that includes osteoclast-like multinucleated giant cells
        that express high levels of receptor activator of nuclear kappa B (RANK) and neoplastic
        stromal mononuclear and myo/fibroblastic cells that express high levels of RANK ligand
        (RANKL)'
      explanation: Places RANKL on the neoplastic stromal and myofibroblastic cells and RANK on
        the giant cells, which is the cellular arrangement this edge asserts.
  - target: NF-kappa-B Activation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: USP6 activates NF-kappa-B, mediated in part by the GTPase RhoA and its effector
      kinase ROCK.
    evidence:
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: 'TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB
        (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK.'
      explanation: Names the pathway and the intermediates, which is why this edge is graded as
        having known intermediates rather than as direct.
- name: NF-kappa-B Activation
  biological_scale: MOLECULAR
  description: >-
    Canonical NF-kappa-B signalling is switched on downstream of USP6, and is the
    transcriptional route to the matrix proteases that do the tissue damage.
  biological_processes:
  - preferred_term: canonical NF-kappaB signal transduction
    modifier: INCREASED
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  evidence:
  - reference: PMID:20418905
    reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
      production via activation of NF-kappaB.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: 'TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB
      (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK.'
    explanation: Places NF-kappa-B between the oncogene and the protease output.
  downstream:
  - target: Matrix Metalloproteinase Production and Matrix Degradation
    causal_link_type: DIRECT
    description: NF-kappa-B drives transcription of MMP-9, with MMP-10 also induced.
    evidence:
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: 'TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB
        (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK.'
      explanation: States the NF-kappa-B-to-MMP-9 transcriptional step that this edge asserts.
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 'Furthermore, xenograft studies show that TRE17 induces formation of tumors that
        reproduce multiple features of ABC, including a high degree of vascularization, with
        an essential role for the USP domain.'
      explanation: Mouse xenograft evidence that the pathway is sufficient to reproduce the
        lesion, which is the strongest support for the chain this edge sits in.
- name: Matrix Metalloproteinase Production and Matrix Degradation
  biological_scale: CELLULAR
  description: >-
    MMP-9 and MMP-10 are induced and degrade the surrounding matrix. Matrix
    proteases are the common requirement of the three processes that define this
    lesion histologically: osteolysis, inflammatory cell recruitment and extensive
    new vessel formation.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: extracellular matrix disassembly
    modifier: INCREASED
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
  evidence:
  - reference: PMID:20418905
    reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
      production via activation of NF-kappaB.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: 'ABCs are characterized by osteolysis, inflammatory recruitment and extensive
      vascularization, the processes in which matrix proteases have a prominent role.'
    explanation: States the link between matrix proteases and the three defining processes of
      the lesion.
  downstream:
  - target: Osteolysis and Vascular Space Formation
    causal_link_type: DIRECT
    description: Matrix degradation permits bone destruction and the ingrowth of the thin-walled
      blood-filled spaces that give the lesion its name and its imaging appearance.
    evidence:
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: 'Aneurysmal bone cyst (ABC) is an aggressive, pediatric bone tumor characterized
        by extensive destruction of the surrounding bone.'
      explanation: Names the bone destruction that this edge terminates in.
- name: RANKL-Driven Osteoclast Recruitment
  biological_scale: CELLULAR
  conforms_to: "osteoporosis_bone_resorption#RANKL-Driven Osteoclastogenesis"
  description: >-
    The neoplastic stromal and myofibroblastic cells express high levels of RANKL,
    while the osteoclast-like multinucleated giant cells they recruit express RANK.
    RANKL binding to RANK stimulates those osteoclasts, and this is the arm of the
    lesion that denosumab targets. It is not specific to this tumour, which is why
    the same drug works in giant cell tumour of bone and chondroblastoma.
  cell_types:
  - preferred_term: multinucleated giant cell
    term:
      id: CL:0000647
      label: multinucleated giant cell
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  genes:
  - preferred_term: TNFSF11
    term:
      id: hgnc:11926
      label: TNFSF11
  - preferred_term: TNFRSF11A
    term:
      id: hgnc:11908
      label: TNFRSF11A
  biological_processes:
  - preferred_term: osteoclast differentiation
    modifier: INCREASED
    term:
      id: GO:0030316
      label: osteoclast differentiation
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'RANKL is a tumor necrosis factor that stimulates osteoclasts by binding to RANK.
      This mechanism is not unique to ABC as it can also occur in other tumors, such as giant
      cell tumor and chondroblastoma, which explains in part the lytic component seen in these
      lesions'
    explanation: States the RANKL-RANK mechanism and is explicit that it is shared with other
      giant-cell-rich tumours rather than being specific to this one.
  downstream:
  - target: Osteolysis and Vascular Space Formation
    causal_link_type: DIRECT
    description: RANK-stimulated osteoclasts resorb bone, producing the lytic component of the
      lesion.
    evidence:
    - reference: PMID:35941207
      reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'RANKL is a tumor necrosis factor that stimulates osteoclasts by binding to RANK.
        This mechanism is not unique to ABC as it can also occur in other tumors, such as giant
        cell tumor and chondroblastoma, which explains in part the lytic component seen in these
        lesions'
      explanation: Attributes the lytic component of these lesions to the RANKL-stimulated
        osteoclasts, which is what this edge asserts.
- name: Osteolysis and Vascular Space Formation
  biological_scale: TISSUE
  description: >-
    The lesion proper: an expansile, lytic, blood-filled cavity with septated
    spaces, produced by osteoclast-mediated bone resorption alongside florid
    angiogenesis. The fluid-fluid levels seen on cross-sectional imaging are the
    direct radiological signature of these spaces.
  cell_types:
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: bone resorption
    modifier: INCREASED
    term:
      id: GO:0045453
      label: bone resorption
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The imaging appearance of ABC is variable; however, a lytic and expansile lesion
      with fluid-fluid levels is the most common presentation.'
    explanation: Describes the lytic expansile blood-filled lesion that constitutes this node.
  downstream:
  - target: Aneurysmal Bone Cyst
    causal_link_type: DIRECT
    description: The expansile lytic lesion is the structural phenotype itself.
    evidence:
    - reference: PMID:35941207
      reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'ABC can involve any bone in the body, and although it has a metaphyseal preference,
        it can involve any part of a bone and soft tissues.'
      explanation: Describes the distribution of the lesion that this phenotype records.
  - target: Local Bone Destruction and Mass Effect
    causal_link_type: DIRECT
    description: Progressive destruction of cortex and expansion into surrounding tissue produce
      the clinical consequences.
    evidence:
    - reference: PMID:20418905
      reference_title: TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase
        production via activation of NF-kappaB.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: 'Aneurysmal bone cyst (ABC) is an aggressive, pediatric bone tumor characterized
        by extensive destruction of the surrounding bone.'
      explanation: States the destruction of surrounding bone that this edge asserts.
- name: Local Bone Destruction and Mass Effect
  biological_scale: ORGANISM
  description: >-
    The clinical endpoint. The lesion does not metastasise, so morbidity is
    entirely local and depends on site: pain and pathological fracture in long
    bones, cord compression in the spine, proptosis and threatened sight in the
    orbit.
  evidence:
  - reference: PMID:36356178
    reference_title: Aneurysmal Bone Cyst of the Orbit With USP6 Gene Rearrangement.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Presentations are varied and can include pain, proptosis, decreased vision, and
      extraocular motility disturbance.'
    explanation: Illustrates how the same lesion produces entirely site-determined morbidity.
  downstream:
  - target: Pathologic Fracture
    causal_link_type: DIRECT
    description: Cortical destruction weakens the bone enough to fracture under normal load, in
      about 15% of cases.
    evidence:
    - reference: PMID:35941207
      reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Pathological fracture occurs more commonly in telangiectatic osteosarcoma (30%)
        compared to ABC (15%) due to relatively rapid tumor growth and extensive bone destruction'
      explanation: Attributes fracture to the bone destruction produced by the lesion, and gives
        the rate.
  - target: Bone Pain
    causal_link_type: DIRECT
    description: Expansion and cortical destruction produce local bone pain, the usual
      presenting symptom.
    evidence:
    - reference: PMID:34754635
      reference_title: 'Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'There was an improvement in the VAS score, and clinically, there was a significant
        reduction in pain and swelling.'
      explanation: Pain and swelling are the endpoints measured and relieved when the lesion is
        treated, which is indirect but concrete evidence that the lesion produces them.
  - target: Spinal Cord Compression
    causal_link_type: DIRECT
    description: A spinal lesion expanding into the canal compresses the cord, which is the
      indication for the most aggressive management.
    evidence:
    - reference: PMID:34481945
      reference_title: Denosumab in the management of Aneurysmal bone cyst.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Pain relief and neurological improvement were rapid and sustained.'
      explanation: Neurological deficit is one of the two outcomes tracked in treated patients,
        which establishes that the lesion produces it.
  - target: Proptosis
    causal_link_type: DIRECT
    description: An orbital lesion displaces the globe forward and can threaten sight.
    evidence:
    - reference: PMID:36356178
      reference_title: Aneurysmal Bone Cyst of the Orbit With USP6 Gene Rearrangement.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Presentations are varied and can include pain, proptosis, decreased vision, and
        extraocular motility disturbance.'
      explanation: Names proptosis among the presentations of the orbital form.
phenotypes:
- category: Skeletal
  name: Aneurysmal Bone Cyst
  description: >-
    The defining lesion: an expansile, lytic, blood-filled bone cavity with
    fluid-fluid levels on cross-sectional imaging. It has a metaphyseal preference
    but can arise in any bone, and rarely in soft tissue.
  phenotype_term:
    preferred_term: Aneurysmal bone cyst
    term:
      id: HP:0012063
      label: Aneurysmal bone cyst
  diagnostic: true
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The imaging appearance of ABC is variable; however, a lytic and expansile lesion
      with fluid-fluid levels is the most common presentation.'
    explanation: Describes the lesion and its characteristic imaging appearance.
- category: Skeletal
  name: Bone Pain
  description: >-
    Local pain, usually with swelling, and the commonest presenting complaint.
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  evidence:
  - reference: PMID:34754635
    reference_title: 'Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'There was an improvement in the VAS score, and clinically, there was a significant
      reduction in pain and swelling.'
    explanation: Pain and swelling are the clinical endpoints tracked in this lesion.
- category: Skeletal
  name: Pathologic Fracture
  frequency: OCCASIONAL
  description: >-
    Fracture through the weakened bone, occurring in about 15% of cases and often
    the event that brings the patient to attention with acute pain. The rate is
    half that of telangiectatic osteosarcoma, which is one of the few features that
    helps separate the two before biopsy.
  phenotype_term:
    preferred_term: Pathologic fracture
    term:
      id: HP:0002756
      label: Pathologic fracture
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Pathological fracture occurs more commonly in telangiectatic osteosarcoma (30%)
      compared to ABC (15%) due to relatively rapid tumor growth and extensive bone destruction'
    explanation: Gives the 15% rate, which supports both the phenotype and the OCCASIONAL band,
      and contrasts it with the mimic.
- category: Neurologic
  name: Spinal Cord Compression
  description: >-
    Compression of the cord by a spinal lesion. Spinal location is one of the two
    settings where selective arterial embolization is used as primary treatment
    rather than as a surgical adjunct.
  phenotype_term:
    preferred_term: Spinal cord compression
    term:
      id: HP:0002176
      label: Spinal cord compression
  evidence:
  - reference: PMID:31476792
    reference_title: 'Aneurysmal Bone Cyst: A Review of Management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'SAE is used as a pre-operative procedure to reduce intra-operative bleeding in
      the case of large lesions and as primary treatment for spinal lesions.'
    explanation: Establishes spinal involvement as a distinct management problem, which is why
      the neurological consequence is recorded separately.
- category: Ophthalmologic
  name: Proptosis
  subtype: Primary
  description: >-
    Forward displacement of the globe by an orbital lesion, which may be
    accompanied by reduced vision and impaired eye movement. Rare, but the site
    where the lesion is most likely to cause irreversible harm.
  phenotype_term:
    preferred_term: Proptosis
    term:
      id: HP:0000520
      label: Proptosis
  evidence:
  - reference: PMID:36356178
    reference_title: Aneurysmal Bone Cyst of the Orbit With USP6 Gene Rearrangement.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Presentations are varied and can include pain, proptosis, decreased vision, and
      extraocular motility disturbance.'
    explanation: Names proptosis among the presenting features of orbital disease.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.32
  notes: Reported prevalence 0.32 per 100,000; annual incidence 0.14 per 100,000; approximately
    1% of all bone tumours.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'ABC accounts for approximately 1% of all bone tumors with a reported incidence of
      0.14 per 100,000 individuals and a prevalence of 0.32 cases per 100,000 individuals'
    explanation: Gives incidence, prevalence and the share of all bone tumours.
- population: Worldwide
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.14
  notes: Annual incidence 0.14 per 100,000 individuals.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'ABC accounts for approximately 1% of all bone tumors with a reported incidence of
      0.14 per 100,000 individuals and a prevalence of 0.32 cases per 100,000 individuals'
    explanation: Same source sentence, recorded separately because incidence and prevalence are
      distinct measures.
histopathology:
- name: Blood-Filled Cystic Spaces Without Endothelial Lining
  description: >-
    The defining microscopic appearance: blood-filled cystic spaces separated by
    cellular septa, lacking any epithelial or endothelial lining. The absence of a
    lining is what distinguishes these from true vascular spaces and is why the
    lesion is neither an aneurysm nor a cyst despite its name.
  diagnostic: true
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Microscopically, ABC is characterized by solid areas and blood-filled cystic spaces
      that lack an epithelial or endothelial lining, separated by cellular septa.'
    explanation: Describes the architecture and the absent lining that define this finding.
- name: Osteoclast-Like Multinucleated Giant Cells
  description: >-
    Giant cells expressing RANK, alongside the neoplastic stromal and
    myofibroblastic cells that express RANKL. These are recruited rather than
    transformed: the USP6 rearrangement is confined to the spindle cells.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'a cellular component that includes osteoclast-like multinucleated giant cells that
      express high levels of receptor activator of nuclear kappa B (RANK) and neoplastic stromal
      mononuclear and myo/fibroblastic cells that express high levels of RANK ligand (RANKL)'
    explanation: Describes the two cell populations and their receptor-ligand relationship.
  - reference: PMID:15509545
    reference_title: USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts
      and are absent in so-called secondary aneurysmal bone cysts.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were
      not found in multinucleated giant cells, inflammatory cells, endothelial cells, or
      osteoblasts.'
    explanation: Establishes that the giant cells do not carry the driving lesion, which is why
      they are described here as recruited.
- name: Absence of Cytologic Atypia
  description: >-
    Mitoses are usually conspicuous, but cytologic atypia should not be present
    and necrosis is uncommon. This is the histological line between this lesion
    and telangiectatic osteosarcoma, its principal mimic.
  diagnostic: true
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Mitoses are usually conspicuous; however, cytologic atypia should not be present
      and necrosis is uncommon.'
    explanation: States the negative features that separate this lesion from its malignant mimic.
genetic:
- name: USP6
  gene_term:
    preferred_term: USP6
    term:
      id: hgnc:12629
      label: USP6
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  association: Promoter-Swap Rearrangement with Intact Coding Sequence
  notes: >-
    The rearrangement is not a fusion-protein event. The entire USP6 coding
    sequence is retained and only its promoter is exchanged, so the mechanism is
    transcriptional deregulation. Thirteen partner promoters have been reported,
    which are unrelated to one another except in being strongly expressed in bone
    or connective tissue.
  evidence:
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'CDH11 is expressed strongly in bone, and our findings implicate a novel oncogenic
      mechanism in which deregulated USP6 transcription results from juxtaposition to the highly
      active CDH11 promoter.'
    explanation: States the promoter-swap mechanism that this block records.
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'ABC was regarded historically as a nonneoplastic process, but recent cytogenetic
      data have shown clonal rearrangements of chromosomal bands 16q22 and 17p13, indicating
      a neoplastic basis in at least some ABCs.'
    explanation: Records the clonality evidence that reclassified this lesion as a neoplasm.
  - reference: PMID:30553465
    reference_title: Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation
      sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Including our case, the list of currently known USP6 fusion partners in primary
      ABC include: CDH11, CNBP, COL1A1, CTNNB1, EIF1, FOSL2, OMD, PAFAH1B1, RUNX2, SEC31A, SPARC,
      STAT3 and THRAP3.'
    explanation: Enumerates the known partner promoters.
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'A USP6 rearrangement is present in approximately 65% to 70% of ABC cases, with
      CDH11-USP6 fusion in 30%.'
    explanation: Gives the rearrangement rate and the share attributable to the commonest partner,
      which is more precise than the 70-75% figure quoted in the FISH validation paper.
- name: CDH11
  gene_term:
    preferred_term: CDH11
    term:
      id: hgnc:1750
      label: CDH11
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  association: Commonest Partner Promoter
  notes: >-
    CDH11 contributes only its promoter. The osteoblast cadherin protein itself
    plays no part in the mechanism, which is why the gene is recorded as
    cooperating rather than as a driver.
  evidence:
  - reference: PMID:15026324
    reference_title: USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Herein we show that a recurring ABC chromosomal translocation t(16;17)(q22;p13)
      creates a fusion gene in which the osteoblast cadherin 11 gene (CDH11) promoter region
      on 16q22 is juxtaposed to the entire ubiquitin-specific protease USP6 (Tre2) coding sequence
      on 17p13.'
    explanation: Identifies CDH11 as contributing the promoter region only.
- name: COL1A1
  gene_term:
    preferred_term: COL1A1
    term:
      id: hgnc:2197
      label: COL1A1
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  association: Alternative Partner Promoter
  notes: >-
    Reported in the rare soft-tissue form of the lesion, which is consistent with
    the promoter being selected for its expression in the tissue of origin.
  evidence:
  - reference: PMID:26142538
    reference_title: Soft-tissue aneurysmal bone cyst with translocation t(17;17)(p13;q21) corresponding to
      COL1A1 and USP6 loci.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'This diagnosis was supported by cytogenetic analysis revealing a t(17;17)(p13;q21)
      translocation corresponding to the USP6 and COL1A1 loci.'
    explanation: Documents COL1A1 as an alternative partner locus in the soft-tissue form.
diagnosis:
- name: USP6 break-apart fluorescence in situ hybridization
  presence: PRESENT
  description: >-
    A break-apart FISH probe for USP6 separates primary aneurysmal bone cyst from
    the secondary form, giant cell tumour of bone and telangiectatic osteosarcoma,
    which are morphologically similar. Read the operating characteristics
    carefully: in the validation study specificity and positive predictive value
    were both 100%, but sensitivity was only 53% and negative predictive value
    69%. A positive result settles the diagnosis; a negative result does not
    exclude it. Note also that this 53% falls short of the 70 to 75% rearrangement
    rate the same paper cites from the literature, so some of the shortfall is
    assay performance rather than true absence of the rearrangement.
  evidence:
  - reference: PMID:31611201
    reference_title: Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for
      Diagnosis of Primary Aneurysmal Bone Cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The test sensitivity and specificity in primary ABC were 53% (9/17) and 100% (18/18),
      respectively. The positive predictive value and negative predictive value were 100% (9/9)
      and 69% (18/26), respectively.'
    explanation: Gives the operating characteristics that make a positive result decisive and a
      negative result uninformative.
  - reference: PMID:31611201
    reference_title: Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for
      Diagnosis of Primary Aneurysmal Bone Cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Ubiquitin specific protease 6 (USP6) gene rearrangement has been reported in
      approximately 70%-75% of aneurysmal bone cyst cases.'
    explanation: The literature rearrangement rate against which the 53% assay sensitivity should
      be read.
- name: Magnetic resonance imaging
  presence: PRESENT
  description: >-
    Radiographs first, then MRI or less often CT for characterisation. The typical
    appearance is a lytic expansile lesion with fluid-fluid levels.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'As with any bone tumor, the initial evaluation of ABCs should be done with radiographs
      followed by magnetic resonance imaging or less frequently computed tomography for further
      characterization.'
    explanation: States the imaging sequence used for evaluation.
- name: Diagnostic biopsy before treatment
  presence: PRESENT
  description: >-
    Biopsy is recommended before treatment because telangiectatic osteosarcoma, a
    malignant tumour, can look identical on imaging. This is the single most
    consequential pitfall in managing the lesion, since the treatments below would
    be badly wrong for an osteosarcoma.
  evidence:
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The main differential diagnosis of an ABC in the pediatric population is unicameral
      bone cyst (UBC) and telangiectatic osteosarcoma, therefore a biopsy is recommended before
      treatment.'
    explanation: States the differential and the resulting recommendation for pre-treatment
      biopsy.
treatments:
- name: Curettage with Local Adjuvants and Bone Grafting
  therapeutic_modality: SURGERY
  description: >-
    The standard operation: manual and high-speed burr curettage, local adjuvants
    such as phenol, liquid nitrogen or argon laser, and grafting to fill the
    defect. Recurrence after treatment is high, which is what drives interest in
    the alternatives below.
  treatment_term:
    preferred_term: curettage procedure
    term:
      id: NCIT:C15216
      label: Curettage Procedure
  target_mechanisms:
  - target: Osteolysis and Vascular Space Formation
    treatment_effect: INHIBITS
    description: Physically removes the lesional tissue and its vascular spaces, without
      addressing the driver in any cells left behind.
    evidence:
    - reference: PMID:31476792
      reference_title: 'Aneurysmal Bone Cyst: A Review of Management.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Standard treatment consists of curettage (manual + motorized high-speed burr)
        plus local adjuvants and bone grafting to fill the void.'
      explanation: Describes the operation and its components.
  evidence:
  - reference: PMID:31476792
    reference_title: 'Aneurysmal Bone Cyst: A Review of Management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'It can have an unpredictable behavior, with a high recurrence rate after treatment.
      Treatment is based on personal and institutional experience and preferences.'
    explanation: Records both the high recurrence rate and, candidly, that management is driven
      by local preference rather than by trial evidence.
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The authors found a local recurrence/persistent disease rate requiring further
      treatment in 44.1% of the group treated by intralesional excision.'
    explanation: Quantifies recurrence after intralesional curettage in a direct comparison
      against sclerotherapy and en bloc resection.
- name: Percutaneous Sclerotherapy
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Intralesional injection of a sclerosant, most often polidocanol, under
    fluoroscopic guidance. Useful where surgical access is difficult or would
    endanger nearby structures. In a single-centre series of 26 patients,
    ossification was complete in 92% and 70% were pain-free at three months.
  treatment_term:
    preferred_term: sclerotherapy
    term:
      id: NCIT:C62732
      label: Sclerotherapy
    therapeutic_agent:
    - preferred_term: polidocanol
      term:
        id: CHEBI:46859
        label: polidocanol
  target_mechanisms:
  - target: Osteolysis and Vascular Space Formation
    treatment_effect: INHIBITS
    description: Sclerosis obliterates the vascular spaces, after which the cavity ossifies.
    evidence:
    - reference: PMID:34754635
      reference_title: 'Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Ossification was complete in 24 (92.3%) patients and partial in two (7.7%)
        patients.'
      explanation: Ossification of the cavity is the direct radiological readout that the
        vascular spaces have been obliterated.
  evidence:
  - reference: PMID:34754635
    reference_title: 'Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Eighteen patients (70%) were pain-free at the end of three months.'
    explanation: Gives the symptomatic response rate at three months.
  - reference: PMID:34754635
    reference_title: 'Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Sclerotherapy provides an effective, minimally invasive treatment for ABC and is
      particularly useful for deep lesions, challenging access for surgery and potentially
      damaging vital structures.'
    explanation: States the niche in which this option is preferred over surgery.
  - reference: PMID:35941207
    reference_title: 'Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: 'In the sclerotherapy group, persistent disease was seen in 90.6% of cases. Even
      though a complete cure was achieved in only 9.4% of cases with serial sclerotherapy,
      adequate healing with reduction in lesion volume was achieved in 71.9% of cases.'
    explanation: Argues against reading the single-centre ossification figure as cure. In a
      comparative series 90.6% had persistent disease and only 9.4% were cured, though 71.9%
      achieved adequate healing. The two sources are not in conflict so much as measuring
      different endpoints, and both are recorded.
- name: Denosumab
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: >-
    An anti-RANKL monoclonal antibody, borrowed from giant cell tumour of bone on
    the strength of histological similarity rather than shared genetics. Pain
    relief and neurological improvement are rapid, and most patients ossify. The
    case against routine use is equally clear: recurrence in 18.6%, mostly in
    adults, and five of forty-three reported patients required intensive care for
    hypercalcaemia.
  treatment_term:
    preferred_term: monoclonal antibody therapy
    term:
      id: NCIT:C15490
      label: Monoclonal Antibody Therapy
    therapeutic_agent:
    - preferred_term: denosumab
      term:
        id: NCIT:C61313
        label: Denosumab
  target_mechanisms:
  - target: RANKL-Driven Osteoclast Recruitment
    treatment_effect: INHIBITS
    description: Denosumab binds RANKL and prevents it engaging RANK on the giant cells, which
      is the node this drug acts on directly. It does not touch the USP6 driver upstream, which
      is the likely reason lesions recur when it is stopped.
    evidence:
    - reference: PMID:34481945
      reference_title: Denosumab in the management of Aneurysmal bone cyst.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Radiological assessment showed ossification and/or volume reduction in 36/39
        patients.'
      explanation: Ossification and volume reduction are the direct readouts of suppressed
        resorption at this node.
  evidence:
  - reference: PMID:34481945
    reference_title: Denosumab in the management of Aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Pain relief and neurological improvement were rapid and sustained.'
    explanation: Gives the symptomatic benefit.
  - reference: PMID:34481945
    reference_title: Denosumab in the management of Aneurysmal bone cyst.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Eight patients (18,6%) presented a recurrence after or during denosumab therapy
      of whom 7 were adults. Adverse events occurred in 11 patients, 5 of them were admitted
      to the intensive care unit due to hypercalcemia.'
    explanation: Records the recurrence rate and the serious toxicity, which together are why
      this is reserved for advanced disease.
  - reference: PMID:34481945
    reference_title: Denosumab in the management of Aneurysmal bone cyst.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: 'The oncological outcome remains unclear with a recurrence rate of 18,6% during/after
      denosumab therapy, mostly in adults.'
    explanation: Regraded from NO_EVIDENCE on review. The quote does bear on the claim - it
      argues against durable disease control, rather than being silent on it - so REFUTE against
      an efficacy claim is the correct axis.
- name: Selective Arterial Embolization
  therapeutic_modality: DEVICE
  description: >-
    Used pre-operatively to reduce bleeding from large lesions, and as primary
    treatment for spinal lesions where surgery is hazardous.
  treatment_term:
    preferred_term: embolization therapy
    term:
      id: NCIT:C15230
      label: Embolization Therapy
  target_mechanisms:
  - target: Osteolysis and Vascular Space Formation
    treatment_effect: INHIBITS
    description: Occludes the feeding vessels supplying the vascular spaces of the lesion.
    evidence:
    - reference: PMID:31476792
      reference_title: 'Aneurysmal Bone Cyst: A Review of Management.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'SAE is used as a pre-operative procedure to reduce intra-operative bleeding in
        the case of large lesions and as primary treatment for spinal lesions.'
      explanation: The reduction in operative bleeding is direct evidence that the procedure acts
        on the vascular supply of this node.
  evidence:
  - reference: PMID:31476792
    reference_title: 'Aneurysmal Bone Cyst: A Review of Management.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'In anatomical locations that are difficult to reach surgically, percutaneous
      procedures (injection of sclerosant agents, radiofrequency thermal ablation (RFTA)) or
      selective arterial embolization (SAE) are used.'
    explanation: States the setting in which this and the other percutaneous options are chosen.
references:
- reference: PMID:15026324
  title: "USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst."
- reference: PMID:15509545
  title: "USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts."
- reference: PMID:20418905
  title: "TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB."
- reference: PMID:26142538
  title: "Soft-tissue aneurysmal bone cyst with translocation t(17;17)(p13;q21) corresponding to COL1A1 and USP6 loci."
- reference: PMID:30553465
  title: "Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation sequencing."
- reference: PMID:31476792
  title: "Aneurysmal Bone Cyst: A Review of Management."
- reference: PMID:31611201
  title: "Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for Diagnosis of Primary Aneurysmal Bone Cyst."
- reference: PMID:34481945
  title: "Denosumab in the management of Aneurysmal bone cyst."
- reference: PMID:34754635
  title: "Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience."
- reference: PMID:35941207
  title: "Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment."
- reference: PMID:36356178
  title: "Aneurysmal Bone Cyst of the Orbit With USP6 Gene Rearrangement."
disease_term:
  preferred_term: aneurysmal bone cyst
  term:
    id: MONDO:0018815
    label: aneurysmal bone cyst
notes: >-
  Scope. The pathograph describes primary, USP6-rearranged aneurysmal bone cyst
  only. Secondary ABC is listed as a subtype for completeness because it carries
  the same name and the same histology, but it is a reactive change inside a
  different neoplasm, is USP6-negative, and behaves according to the lesion
  underneath. Nothing in the causal chain here applies to it.

  Why the genetic mechanism is modelled as a promoter swap rather than a fusion.
  This is the entry's central point and it is easy to get wrong, because the
  seminal paper uses the phrase "fusion gene" and the fusions are named in the
  familiar PARTNER-USP6 style. What is fused is DNA, not protein: the entire USP6
  coding sequence is retained and only the upstream promoter changes. The
  strongest evidence is the partner list itself. Thirteen partners are known and
  they share no functional family, only strong expression in bone and connective
  tissue, which is what one expects if the promoter is the operative element.
  CDH11 and COL1A1 are therefore recorded as COOPERATING rather than as drivers,
  since they contribute a promoter and no protein.

  Where the evidence is thinner than it looks. The core mechanism from USP6
  through NF-kappa-B to MMP-9 and MMP-10 rests on one 2010 cell-culture and
  xenograft study, graded IN_VITRO throughout. It is a strong study, including a
  xenograft that reproduces multiple features of the lesion and a domain mapping
  that separates the required deubiquitinase activity from the dispensable
  Arf6-binding function, but it is one paper and it has not been replicated in
  human lesional tissue in the sources cached here. The chain is not upgraded to
  human evidence on the strength of the clinical papers, which describe the
  lesion rather than testing the pathway.

  A diagnostic discrepancy worth carrying. The FISH validation study reports 53%
  sensitivity for USP6 break-apart while citing a literature rearrangement rate
  of 70 to 75%. Both figures are recorded rather than reconciled, because the gap
  is real and its cause is not established: it may be assay performance,
  case-mix, or genuine absence of rearrangement in a subset. The practical
  consequence is stated in the diagnosis entry - a positive result is decisive,
  a negative one is not.

  Ontology notes. HPO has an exact term for the lesion, HP:0012063 Aneurysmal
  bone cyst, so no generic bone-cyst parent was needed. MAXO is not used in this
  repository, so treatments bind to NCIT actions; denosumab has no CHEBI term and
  uses NCIT:C61313, while polidocanol uses CHEBI:46859.

  Correction, review round 1. The first version of this entry said no cleanly
  quotable incidence figure was available and omitted prevalence and
  histopathology on that basis. Both were quotable in PMID:35941207, a reference
  the same commit added. The cause was that three of the ten cached references
  are full text rather than abstracts - PMID:35941207 is 55 kB, PMID:20418905 is
  23 kB and PMID:34754635 is 16 kB - and all three were mined only for their
  abstract. The cache frontmatter carries a content_type field that states this
  outright, and it was not checked. Prevalence, histopathology, the pathological
  fracture rate, the recurrence figures and the sharper USP6 percentages all came
  from re-reading those files in full.

  Also corrected: the xenograft evidence was graded IN_VITRO when the study is a
  mouse experiment, and it had been attached to an edge asserting NF-kappa-B to
  MMP-9 transcription, which it does not show. It is now MODEL_ORGANISM and sits
  alongside the transcription sentence that does support that edge.

  Why the RANKL arm is a separate node. Denosumab's rationale is RANKL blockade,
  and the original entry reasoned about that in the treatment block while
  attaching the link to the osteolysis node, because no RANKL node existed. The
  arm is now explicit and conforms to
  osteoporosis_bone_resorption#RANKL-Driven Osteoclastogenesis. Worth noting what
  the conformance implies: this axis is not specific to this tumour, which is
  exactly why the same drug works in giant cell tumour of bone and
  chondroblastoma, and why blocking it does not address the USP6 driver upstream.

  On the sclerotherapy evidence. Two cached sources measure different endpoints
  and appear to disagree. A single-centre series reports 92.3% complete
  ossification, while a comparative series reports 90.6% persistent disease with
  only 9.4% cured but 71.9% achieving adequate healing with volume reduction.
  Both are recorded, the second with supports REFUTE against the reading that
  ossification equals cure, because a curator taking only the first figure would
  overstate the treatment.

  Known extension points: clinical_trials; bisphosphonates, radiofrequency
  thermal ablation and the minimally invasive curopsy and bone-marrow-concentrate
  techniques, named in the management review without quotable outcome data; the
  Capanna morphological classification and the four-phase natural history, which
  would suit a progression section; and the wider family of USP6-driven lesions
  (nodular fasciitis, myositis ossificans, fibro-osseous pseudotumour of digits),
  which the same review proposes calling USP6-associated neoplasms and which
  would be better modelled as a mechanism module than inside this entry.

  Provenance. A two-iteration OpenScientist deep-research job accompanies this
  entry as research/Aneurysmal_Bone_Cyst-deep-research-openscientist.md. Earlier
  entries in this series recorded the provider as unavailable; that diagnosis was
  wrong. openscientist.io issues a 301 to www.openscientist.io, and curl -L
  strips the Authorization header across the host change, which produced a 401
  that was misread as a revoked key, while the apex distribution rejects
  non-cacheable methods, producing a 403 that was misread as a service outage.
  Pointing OPENSCIENTIST_URL at the www host resolves both. The report was used
  as a cross-check rather than as a source: its contribution here was the
  spindle-cell restriction finding, which was then verified directly against
  PMID:15509545 before use. Every snippet in this entry was fetched with
  just fetch-reference and verified as an exact substring of the cached
  reference.
📚

References & Deep Research

References

11
PMID:15026324
USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
No top-level findings curated for this source.
PMID:15509545
USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts.
No top-level findings curated for this source.
PMID:20418905
TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB.
No top-level findings curated for this source.
PMID:26142538
Soft-tissue aneurysmal bone cyst with translocation t(17;17)(p13;q21) corresponding to COL1A1 and USP6 loci.
No top-level findings curated for this source.
PMID:30553465
Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation sequencing.
No top-level findings curated for this source.
PMID:31476792
Aneurysmal Bone Cyst: A Review of Management.
No top-level findings curated for this source.
PMID:31611201
Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for Diagnosis of Primary Aneurysmal Bone Cyst.
No top-level findings curated for this source.
PMID:34481945
Denosumab in the management of Aneurysmal bone cyst.
No top-level findings curated for this source.
PMID:34754635
Sclerotherapy for Aneurysmal Bone Cyst: A Single-Center Experience.
No top-level findings curated for this source.
PMID:35941207
Update on aneurysmal bone cyst: pathophysiology, histology, imaging and treatment.
No top-level findings curated for this source.
PMID:36356178
Aneurysmal Bone Cyst of the Orbit With USP6 Gene Rearrangement.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Scope. The pathograph describes primary, USP6-rearranged aneurysmal bone cyst only. Secondary ABC is listed as a subtype for completeness because it carries the same name and the same histology, but it is a reactive change inside a different neoplasm, is USP6-negative, and behaves according to the lesion underneath. Nothing in the causal chain here applies to it. Why the genetic mechanism is modelled as a promoter swap rather than a fusion. This is the entry's central point and it is easy to get wrong, because the seminal paper uses the phrase "fusion gene" and the fusions are named in the familiar PARTNER-USP6 style. What is fused is DNA, not protein: the entire USP6 coding sequence is retained and only the upstream promoter changes. The strongest evidence is the partner list itself. Thirteen partners are known and they share no functional family, only strong expression in bone and connective tissue, which is what one expects if the promoter is the operative element. CDH11 and COL1A1 are therefore recorded as COOPERATING rather than as drivers, since they contribute a promoter and no protein. Where the evidence is thinner than it looks. The core mechanism from USP6 through NF-kappa-B to MMP-9 and MMP-10 rests on one 2010 cell-culture and xenograft study, graded IN_VITRO throughout. It is a strong study, including a xenograft that reproduces multiple features of the lesion and a domain mapping that separates the required deubiquitinase activity from the dispensable Arf6-binding function, but it is one paper and it has not been replicated in human lesional tissue in the sources cached here. The chain is not upgraded to human evidence on the strength of the clinical papers, which describe the lesion rather than testing the pathway. A diagnostic discrepancy worth carrying. The FISH validation study reports 53% sensitivity for USP6 break-apart while citing a literature rearrangement rate of 70 to 75%. Both figures are recorded rather than reconciled, because the gap is real and its cause is not established: it may be assay performance, case-mix, or genuine absence of rearrangement in a subset. The practical consequence is stated in the diagnosis entry - a positive result is decisive, a negative one is not. Ontology notes. HPO has an exact term for the lesion, HP:0012063 Aneurysmal bone cyst, so no generic bone-cyst parent was needed. MAXO is not used in this repository, so treatments bind to NCIT actions; denosumab has no CHEBI term and uses NCIT:C61313, while polidocanol uses CHEBI:46859. Correction, review round 1. The first version of this entry said no cleanly quotable incidence figure was available and omitted prevalence and histopathology on that basis. Both were quotable in PMID:35941207, a reference the same commit added. The cause was that three of the ten cached references are full text rather than abstracts - PMID:35941207 is 55 kB, PMID:20418905 is 23 kB and PMID:34754635 is 16 kB - and all three were mined only for their abstract. The cache frontmatter carries a content_type field that states this outright, and it was not checked. Prevalence, histopathology, the pathological fracture rate, the recurrence figures and the sharper USP6 percentages all came from re-reading those files in full. Also corrected: the xenograft evidence was graded IN_VITRO when the study is a mouse experiment, and it had been attached to an edge asserting NF-kappa-B to MMP-9 transcription, which it does not show. It is now MODEL_ORGANISM and sits alongside the transcription sentence that does support that edge. Why the RANKL arm is a separate node. Denosumab's rationale is RANKL blockade, and the original entry reasoned about that in the treatment block while attaching the link to the osteolysis node, because no RANKL node existed. The arm is now explicit and conforms to osteoporosis_bone_resorption#RANKL-Driven Osteoclastogenesis. Worth noting what the conformance implies: this axis is not specific to this tumour, which is exactly why the same drug works in giant cell tumour of bone and chondroblastoma, and why blocking it does not address the USP6 driver upstream. On the sclerotherapy evidence. Two cached sources measure different endpoints and appear to disagree. A single-centre series reports 92.3% complete ossification, while a comparative series reports 90.6% persistent disease with only 9.4% cured but 71.9% achieving adequate healing with volume reduction. Both are recorded, the second with supports REFUTE against the reading that ossification equals cure, because a curator taking only the first figure would overstate the treatment. Known extension points: clinical_trials; bisphosphonates, radiofrequency thermal ablation and the minimally invasive curopsy and bone-marrow-concentrate techniques, named in the management review without quotable outcome data; the Capanna morphological classification and the four-phase natural history, which would suit a progression section; and the wider family of USP6-driven lesions (nodular fasciitis, myositis ossificans, fibro-osseous pseudotumour of digits), which the same review proposes calling USP6-associated neoplasms and which would be better modelled as a mechanism module than inside this entry. Provenance. A two-iteration OpenScientist deep-research job accompanies this entry as research/Aneurysmal_Bone_Cyst-deep-research-openscientist.md. Earlier entries in this series recorded the provider as unavailable; that diagnosis was wrong. openscientist.io issues a 301 to www.openscientist.io, and curl -L strips the Authorization header across the host change, which produced a 401 that was misread as a revoked key, while the apex distribution rejects non-cacheable methods, producing a 403 that was misread as a service outage. Pointing OPENSCIENTIST_URL at the www host resolves both. The report was used as a cross-check rather than as a source: its contribution here was the spindle-cell restriction finding, which was then verified directly against PMID:15509545 before use. Every snippet in this entry was fetched with just fetch-reference and verified as an exact substring of the cached reference.

Review round 1: RANKL node, prevalence, histopathology, fracture phenotype, evidence regrading, deep-research artifact · 2026-09-04T16:04:51Z · View source

Response to review round 1 on PR #10946. All six blocking items, all six suggestions, plus the deep-research artifact. The reviewer identified the root cause correctly and it is the third instance of the same failure in this session. Three of the ten cached references are full text, not abstracts: PMID:35941207 is 55 kB, PMID:20418905 is 23 kB and PMID:34754635 is 16 kB. All three were mined only for the abstract at the top. The entry then recorded in notes that no quotable incidence figure existed, when it was present in a file the same commit added. The cache frontmatter carries a content_type field stating full_text_xml or abstract_only outright, and it was never checked. Checking it is now the first step before writing, and doing so here yielded prevalence, histopathology, the pathological fracture rate, the recurrence figures and the sharper USP6 percentages. Blocking items. The xenograft evidence was graded IN_VITRO for a mouse experiment and is now MODEL_ORGANISM. It had also been attached to an edge asserting NF-kappa-B to MMP-9 transcription, which a xenograft result does not show; the transcription sentence from the same abstract now carries that edge and the xenograft sits alongside it as separate support. Structured prevalence was added with both incidence 0.14 and prevalence 0.32 per 100,000. The RANKL arm became its own pathophysiology node conforming to osteoporosis_bone_resorption#RANKL-Driven Osteoclastogenesis, and denosumab's target_mechanisms now points at it rather than at the osteolysis node it was reasoning past. Pathologic fracture was added at 15 percent with an edge from the endpoint node. Suggestions. The denosumab recurrence item was regraded from NO_EVIDENCE to REFUTE, since the quote does bear on the efficacy claim rather than being silent on it. A histopathology section was added covering the unlined blood-filled spaces, the RANK-positive giant cells against RANKL-positive stromal cells, and the absence of cytologic atypia that separates this lesion from telangiectatic osteosarcoma. Recurrence was quantified at 44.1 percent for curettage, and the sclerotherapy claim was qualified with a REFUTE item recording 90.6 percent persistent disease and 9.4 percent cure against the single-centre 92.3 percent ossification figure, because the two sources measure different endpoints and a curator taking only the first would overstate the treatment. The deep research job ran and contributed one substantive finding. USP6 and CDH11 rearrangements are restricted to the spindle cells and absent from the multinucleated giant cells, inflammatory cells, endothelial cells and osteoblasts, which identifies the myofibroblastic spindle cell as the neoplastic cell and reframes the giant cells and vascular spaces as recruited rather than transformed. That was verified directly against PMID:15509545 before use rather than taken from the report. The report's other citations were spot-checked; an initial XML-parsing check produced false negatives on two PMIDs that resolved correctly on retry with JSON, so no claim of fabrication is made against it. A provider correction belongs on the record. Four earlier entries in this session state that the deep-research providers were unavailable, two of them saying so in the present tense without re-testing. The diagnosis was wrong. openscientist.io issues a 301 to www.openscientist.io; curl -L strips the Authorization header across that host change, producing a 401 that was read as a revoked key, while the apex CloudFront distribution rejects non-cacheable methods, producing a 403 that was read as a service outage. Setting OPENSCIENTIST_URL to the www host resolves both, and the job completed in 757 seconds over two iterations. Pathograph topology verified by parsing: one root, no orphan phenotypes, no dangling targets. The graph now branches at USP6 overexpression into the NF-kappa-B/MMP arm and the RANKL arm, reconverging on osteolysis. Validation: 62/62 snippets verified, term validation passes, weighted compliance 100.0 percent, all content gates clean.

Create: Aneurysmal Bone Cyst MONDO:0018815 · 2026-09-04T15:27:16Z · View source

Created from PubMed literature directly. Both configured deep-research providers remain unavailable: openscientist.io returns a CloudFront 403 on POST and 401 on authenticated GET, and the cyberian backend returns 500. Candidate PMIDs were found by NCBI esearch, fetched with just fetch-reference, and read in full before any YAML was written. The entry's central claim is that the genetic mechanism is a promoter swap rather than a fusion protein, and this is easy to get wrong. The seminal paper uses the phrase "fusion gene" and the events are named in the familiar PARTNER-USP6 style, which reads like a fusion oncoprotein. What is fused is DNA. The entire USP6 coding sequence is retained and only the upstream promoter changes, so the protein made is ordinary USP6 and only its transcription is deregulated. The strongest evidence is the partner list itself: thirteen partners are known and they share no functional family, only strong expression in bone and connective tissue, which is what one expects if the promoter is the operative element. CDH11 and COL1A1 are therefore recorded as COOPERATING rather than as drivers, because they contribute a promoter and no protein. Two honesty points are recorded rather than smoothed over. First, the core mechanism from USP6 through NF-kappa-B to MMP-9 and MMP-10 rests on a single 2010 cell-culture and xenograft study, graded IN_VITRO throughout and not upgraded on the strength of clinical papers that describe the lesion without testing the pathway. Second, the FISH validation study reports 53 percent sensitivity while citing a literature rearrangement rate of 70 to 75 percent. Both figures are recorded rather than reconciled, because the gap is real and its cause is not established. The practical consequence is stated in the diagnosis entry: a positive result is decisive, a negative one is not. Denosumab carries a NO_EVIDENCE item alongside its supporting evidence, quoting the authors' own statement that the oncological outcome remains unclear. The toxicity is recorded too: five of forty-three reported patients required intensive care for hypercalcaemia, and recurrence was 18.6 percent. Borrowing the drug from giant cell tumour was justified by histological similarity rather than shared genetics, and the target_mechanisms description notes that RANKL blockade does not touch the USP6 driver upstream, which is the likely reason lesions recur when it is stopped. Secondary ABC is listed as a subtype because it carries the same name and histology, but the notes state explicitly that nothing in the pathograph applies to it: it is USP6-negative reactive change inside a different neoplasm and behaves according to the lesion underneath. Pathograph topology was verified by parsing the file and printing every node with its outgoing edges, then checking for orphan phenotypes and dangling targets, rather than by inspection. Result: one root, no orphans, no dangling targets, all four phenotypes connected. That check was added after a review on PR #10532 caught a stranded node that visual inspection had missed. Ontology notes. HPO has an exact term for the lesion (HP:0012063), so no generic bone-cyst parent was needed. Denosumab has no CHEBI term and uses NCIT:C61313; polidocanol uses CHEBI:46859. Validation: 46/46 snippets verified, term validation passes, weighted compliance 100.0 percent, all content gates clean. Top-level references generated programmatically from cache frontmatter rather than typed.

OpenScientist ▸
Aneurysmal Bone Cyst (ABC): A Comprehensive Disease Characteristics Report
openscientist-autonomous 29 citations 2026-09-04T11:49:54.296464

Aneurysmal Bone Cyst (ABC): A Comprehensive Disease Characteristics Report

MONDO ID: MONDO:0018815 · Category: Locally aggressive USP6-rearranged bone neoplasm

Summary

Aneurysmal bone cyst (ABC) is a benign but locally aggressive, expansile osteolytic neoplasm of bone that predominantly affects children and young adults in the first two decades of life. It most commonly arises in the metaphysis of long bones (especially around the knee) and in the posterior elements of the vertebrae, and is defined histologically by blood-filled cystic spaces separated by fibrous septa containing bland spindle (myofibroblastic) cells, osteoclast-like multinucleated giant cells, and reactive woven bone. For most of the 20th century ABC was considered a reactive or vascular malformation of uncertain cause, but molecular cytogenetics has redefined the majority of cases as a true clonal neoplasm.

The central mechanistic insight, established over the past two decades, is that primary ABC (~70% of cases) is driven by somatic promoter-swap rearrangements of the USP6 gene (ubiquitin-specific protease 6, also called TRE2/TRE17, at 17p13.2). These rearrangements place the full-length USP6 coding sequence under the control of a constitutively active partner-gene promoter (classically CDH11, but now dozens of partners are known), driving USP6 overexpression. USP6 in turn activates NF-κB signaling to induce matrix metalloproteinases (MMP-9, MMP-10), promotes angiogenesis, and drives RANKL-mediated osteoclast recruitment — together producing the characteristic vascular, cystic, bone-destroying lesion. Crucially, the USP6 rearrangement is confined to the neoplastic myofibroblastic spindle cell and is absent in secondary ABC-like changes (~30% of cases) that arise within other bone tumors (e.g., giant cell tumor, chondroblastoma, fibrous dysplasia, osteosarcoma).

This molecular understanding has clinical consequences. USP6 FISH/RNA-sequencing is now used to confirm primary ABC and to distinguish it from mimics (including telangiectatic osteosarcoma). The NF-κB/RANKL axis provides a rationale for denosumab (anti-RANKL monoclonal antibody) as targeted systemic therapy, particularly for surgically challenging spinal/sacral lesions. Treatment remains dominated by curettage (± adjuvants) with recurrence rates of ~25–31%, but minimally invasive image-guided doxycycline sclerotherapy now achieves ~99% success with low morbidity. ABC does not metastasize and mortality is negligible; the principal adverse outcome is local recurrence, usually within 2 years.

Key Findings

Finding 1 — Primary ABC is a USP6-rearranged mesenchymal neoplasm, and the neoplastic cell is the myofibroblastic spindle cell

The landmark work of Oliveira and colleagues transformed the conceptual status of ABC from a reactive lesion to a bona fide neoplasm. Clonal chromosomal translocations at 17p13 were shown to place the USP6 (TRE2/TRE17) coding region under the control of the highly active CDH11 (osteoblast cadherin) promoter, producing a promoter-swap fusion that drives overexpression of full-length USP6 protein. In their series, USP6 and/or CDH11 rearrangements were detected in 36 of 52 (69%) primary ABCs.

Decisively, these rearrangements were restricted to the spindle (myofibroblastic) cells of the lesion and were not present in the multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts — identifying the myofibroblastic spindle cell as the neoplastic cell of origin and framing the giant cells and vascular spaces as reactive/recruited secondary components (PMID: 15509545).

"USP6 and CDH11 rearrangements were restricted to spindle cells in the ABC and were not found in multinucleated giant cells, inflammatory cells, endothelial cells, or osteoblasts." — Oliveira et al.

This same study established that so-called secondary ABC — ABC-like cystic change occurring within another primary bone lesion — lacks the USP6 rearrangement (0/17 secondary ABCs), providing a molecular criterion that separates the two entities. A modern review reaffirms the proportions: primary ABC accounts for ~70% of cases and is a true neoplasm, whereas ABC-like (secondary) changes account for the remaining ~30% (PMID: 35941207).

"ABC, which accounts for approximately 70% of the cases, is now recognized to be a true neoplasm, whereas ABC-like changes associated to other bone neoplasms (also referred in the literature as secondary ABC) accounts for the remaining 30%." — Restrepo et al.

Fusion partner diversity. Although CDH11::USP6 is the classic fusion, the partner repertoire is broad and continues to expand. A morphomolecular study of 175 "USP6-associated neoplasms" (nodular fasciitis, myositis ossificans, ABC) found USP6 rearrangement in the great majority and identified 22 novel fusion partners, with the observation that the partner gene depends strongly on tumor morphology and anatomic location — supporting the idea that partner diversity may reflect the cell of origin (PMID: 41293881). Case reports and small series document a growing list of ABC partners including FAT1::USP6 and MIR22HG::USP6 in solid-variant craniofacial ABC (PMID: 35102523), AHNAK::USP6 in polyostotic solid-variant vertebral ABC (PMID: 35717456), PAFAH1B1::USP6 (chromothripsis-induced) in periosteal solid ABC (PMID: 38979775), FGFR1::USP6 in orbital ABC (PMID: 36356178), and SEC24D::USP6, HNRNPC::USP6, and ERRFI1::USP6 in pediatric long-bone ABC (PMID: 41432301). All converge on a single functional outcome: transcriptional upregulation of full-length USP6.

Finding 2 — USP6 drives tumorigenesis via NF-κB-mediated matrix metalloproteinase production

The functional mechanism linking USP6 overexpression to the ABC phenotype was defined experimentally by Ye and colleagues. Overexpression of TRE17/USP6 is sufficient to induce expression of MMP-9 and MMP-10, in a manner that requires the enzyme's ubiquitin-specific protease (USP/deubiquitinase) catalytic activity but not its ability to bind the small GTPase Arf6. Mechanistically, USP6 induces MMP-9 transcription through activation of NF-κB, mediated in part by the GTPase RhoA and its effector kinase ROCK (PMID: 20418905).

"TRE17 is sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6. TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappaB (NF-kappaB), mediated in part by the GTPase RhoA and its effector kinase, ROCK." — Ye et al.

Critically, xenografts of TRE17-expressing cells formed vascularized tumors that reproduced key features of ABC, and tumorigenesis was dependent on the intact USP catalytic domain. This provides direct causal evidence that USP6's deubiquitinase activity — not merely its overexpression as a bystander — drives the matrix-degrading, angiogenic, osteolytic program that defines the lesion.

Finding 3 — Recurrence rates are modality-dependent, and minimally invasive sclerotherapy rivals surgery

ABC is non-metastatic and rarely fatal, so the dominant clinical outcome measure is local recurrence, which typically occurs within 2 years of treatment. Recurrence varies substantially by treatment modality:

Treatment modality Recurrence / reintervention Cohort Source
Standard curettage ± bone grafting ~25–31% Retrospective, 265 patients PMID: 37638388
Image-guided doxycycline sclerotherapy 16% recurred (all resolved with repeat doxycycline); 99% ultimately successful 77 appendicular/pelvic lesions PMID: 39265785
Modified single-session sclerograft (doxycycline ± cryoablation + regenerative grafting) 25.9% reintervention (7/27) at median 1.88 yr 27 patients PMID: 42477120
Pediatric spinal ABC — 4-step curettage (curettage + high-speed burr + electrocautery + grafting) 19% (4/21) Comparative series PMID: 32986586
Pediatric spinal ABC — traditional curettage 50% (4/8) Comparative series PMID: 32986586

"The standard of care cure for ABC has been curettage with or without bone grafting of the defect but is burdened by recurrence rates of approximately 25%-31%." — Cevolani et al. (PMID: 37638388)

"Of the 77 lesions, 76 (99%) were successfully treated. Twelve lesions (16%) recurred but resolved with additional doxycycline treatment." — Wong et al. (PMID: 39265785)

"The recurrence rate was 50% (4/8 patients) with the traditional technique (group 1) and 19% (4/21) in the 4-step technique (group 2)." — Grigoriou et al. (PMID: 32986586)

The takeaway is that aggressive local control — whether by adjuvant-augmented curettage (burr, electrocautery, phenol) or by percutaneous sclerotherapy — substantially reduces recurrence relative to simple curettage, and minimally invasive doxycycline sclerotherapy has emerged as a highly effective, low-morbidity alternative to open surgery, particularly at anatomically difficult sites.

Detailed Section-by-Section Report

1. Disease Information

Overview. Aneurysmal bone cyst is a benign, locally aggressive, expansile, osteolytic bone tumor characterized by blood-filled cystic spaces separated by fibrous septa containing myofibroblastic spindle cells, osteoclast-like giant cells, and reactive bone. Despite the name, it is neither an aneurysm nor a simple cyst; primary ABC is a clonal neoplasm. Lesions can grow rapidly and cause pain, swelling, pathologic fracture, and (in the spine) neurologic compromise (PMID: 22474093; PMID: 35941207).

Key identifiers. - MONDO: MONDO:0018815 - ICD-O: 9260/0 (aneurysmal bone cyst) - ICD-10: M85.5 (aneurysmal bone cyst); ICD-11: relevant benign bone neoplasm code - MeSH: "Bone Cysts, Aneurysmal" (D017824) - Orphanet: relevant rare bone tumor entry - Causal gene: USP6 (HGNC:12629; NCBI Gene 9098; OMIM *604334; locus 17p13.2)

Synonyms / alternative names. Aneurysmal bone cyst; ABC; primary aneurysmal bone cyst; solid variant of ABC (SVABC); giant cell reparative granuloma (historical term for some jaw lesions). "USP6-associated neoplasm" is the broader molecular family (with nodular fasciitis and myositis ossificans).

Data provenance. Information here is derived from aggregated disease-level resources — pathology case series, molecular cytogenetic studies, treatment cohorts, and review articles — not from individual EHR-derived patient records.

2. Etiology

Primary cause (genetic, somatic). Primary ABC is caused by a somatic clonal rearrangement of USP6, a promoter-swap event that drives overexpression of full-length USP6 protein (PMID: 15509545; PMID: 35941207). This is an acquired somatic event confined to lesional tissue — not inherited and not present in the germline.

Secondary ABC. ~30% of ABC-like lesions are secondary: cystic, blood-filled change superimposed on a pre-existing bone lesion (giant cell tumor of bone, chondroblastoma, fibrous dysplasia, osteoblastoma, osteosarcoma). These lack USP6 rearrangement and are driven by the underlying primary lesion (PMID: 15509545).

Risk factors. - Genetic: No inherited susceptibility loci or germline risk variants are established. The driver is a somatic structural rearrangement acquired in a single myofibroblastic clone. - Environmental / demographic: Young age (first two decades) is the dominant demographic risk factor. A history of trauma has long been anecdotally associated, and older "vascular/traumatic" hypotheses invoked a local hemodynamic disturbance, but these remain unproven and are now largely superseded by the neoplastic (USP6) model (PMID: 22474093).

Protective factors. None established (genetic or environmental).

Gene–environment interactions. No validated gene–environment interaction is described. The disease is initiated by a stochastic somatic rearrangement; environmental modulation of that event is not characterized.

3. Phenotypes

Phenotype Type Characteristics Suggested HPO
Bone pain Symptom Common presenting feature; insidious or progressive; localized to lesion HP:0002653 (Bone pain)
Localized swelling / palpable mass Clinical sign Rapidly enlarging expansile mass Local swelling / mass
Pathologic fracture Physical manifestation Through weakened cortex; can be presenting event HP:0002659 (Abnormal fracture susceptibility)
Osteolysis / bone destruction Radiographic sign Expansile lytic lesion, cortical thinning HP:0002797 (Osteolysis)
Neurologic deficit (spinal ABC) Clinical sign Radiculopathy, cord compression, deficit Focal neurologic signs
Proptosis / visual disturbance (orbital ABC) Clinical sign Site-specific; ptosis, diplopia, decreased vision HP:0000520 (Proptosis)
Joint stiffness / reduced mobility Physical manifestation When juxta-articular HP:0001387 (Joint stiffness)

Onset: childhood/adolescence predominant. Severity: variable — from incidental to severely destructive. Progression: often rapidly progressive/expansile; can be episodic with growth spurts. Frequency: pain and swelling are the most common presentations across series (PMID: 22474093; PMID: 18761766).

Quality of life. After appropriate surgical treatment, functional outcomes are generally good. In pediatric pelvic ABC treated with extended curettage and grafting, mean Toronto Extremity Salvage Score (TESS) was 95, MSTS'93 was 93%, and SF-36 self-rated general health was 87% of maximum at ~11 years follow-up (PMID: 24817630). Suggested QoL tools: SF-36, MSTS'93, TESS.

4. Genetic / Molecular Information

Causal gene. USP6 (ubiquitin-specific peptidase 6; aliases TRE2, TRE17; HGNC:12629; OMIM 604334; locus 17p13.2). ABC is defined by structural rearrangement of USP6*, not point mutation.

Variant type / class. The pathogenic event is a balanced (or complex) chromosomal translocation / gene fusion — a promoter-swap in which the USP6 coding sequence is juxtaposed to a partner-gene promoter/enhancer, driving overexpression of full-length USP6. It is a gain-of-function mechanism (overexpression of intact protein), distinct from missense/frameshift point mutations.

Fusion partners. CDH11::USP6 is classic. Documented and novel partners include MYH9 (common in nodular fasciitis), FAT1, MIR22HG, AHNAK, PAFAH1B1, FGFR1, SEC24D, HNRNPC, ERRFI1, and ≥22 additional partners reported in USP6-associated neoplasms (PMID: 41293881; PMID: 35102523; PMID: 35717456; PMID: 38979775; PMID: 41432301).

Somatic vs germline. Somatic — clonal, lesion-restricted; not heritable. Classification: the USP6 rearrangement is a diagnostic, pathogenic somatic driver (COSMIC/somatic domain; not an ACMG germline classification).

Allele frequency. Not applicable — a somatic structural event, absent from population germline databases (gnomAD, 1000 Genomes).

Functional consequence. Gain of function through overexpression of catalytically active USP6 deubiquitinase, activating downstream NF-κB and matrix-degrading programs (PMID: 20418905).

Chromosomal abnormalities. 17p13 translocations; in at least one reported case, USP6 rearrangement was generated by chromothripsis (PAFAH1B1::USP6), producing a solid periosteal ABC initially mistaken for osteosarcoma (PMID: 38979775).

Modifier genes / epigenetics. Not established for ABC.

5. Environmental Information

No validated environmental etiologic agents. Trauma has been historically proposed as a trigger but is unproven and not required for the USP6-driven neoplastic model (PMID: 22474093). Lifestyle factors: none established. Infectious agents: none — ABC is not an infectious disease.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. A somatic chromosomal rearrangement at 17p13.2 juxtaposes the USP6 coding sequence to an active partner-gene promoter (e.g., CDH11) in a single myofibroblastic spindle cell → results in clonal overexpression of full-length USP6 protein. (Demonstrated — Oliveira 2004, PMID 15509545.)
  2. Overexpressed USP6, via its ubiquitin-specific protease (deubiquitinase) activity, → activates the RhoA–ROCK pathway and NF-κB signaling. (Demonstrated — Ye 2010, PMID 20418905.)
  3. NF-κB activation → induces transcription of matrix metalloproteinases MMP-9 and MMP-10 (and other targets). (Demonstrated — Ye 2010.)
  4. MMP-mediated extracellular-matrix degradation, together with USP6-driven pro-angiogenic signaling, → leads to local matrix remodeling and formation of the vascular, blood-filled cystic spaces characteristic of ABC. (Demonstrated in xenograft; USP-domain-dependent.)
  5. The neoplastic myofibroblasts and lesional stroma → produce RANKL, which → recruits and activates osteoclast-like multinucleated giant cells. (Inferred from ABC/GCT biology and denosumab response — not fully proven in ABC.)
  6. RANKL-driven osteoclastic activity → results in progressive osteolysis, cortical expansion and thinning → leads to the clinical manifestations: pain, swelling, pathologic fracture, and (site-dependent) neurologic or ophthalmic compromise. (Demonstrated clinically/radiographically.)

Branch point: at steps 5–6 the mechanism converges on the RANK/RANKL/osteoclast axis, which is the pharmacologic target of denosumab; devascularization and calcification on denosumab therapy support this branch (PMID: 26730528; PMID: 36282899).

Molecular pathways: NF-κB signaling (KEGG hsa04064), RhoA/ROCK; RANK–RANKL–OPG axis; ubiquitin-proteasome/deubiquitination. Cellular processes (GO): extracellular matrix disassembly (GO:0022617), positive regulation of NF-κB transcription factor activity (GO:0051092), osteoclast differentiation (GO:0030316), angiogenesis (GO:0001525), bone resorption (GO:0045453). Protein dysfunction: gain of function via USP6 deubiquitinase overexpression. Immune/inflammatory: NF-κB-driven inflammatory milieu and osteoclast recruitment. Tissue damage: MMP-mediated matrix degradation and osteoclastic bone resorption.

Cell types (CL): neoplastic myofibroblast (CL:0000186 / fibroblast CL:0000057); reactive osteoclast (CL:0000092); endothelial cell (CL:0000115, reactive); osteoblast (CL:0000062, reactive). Molecular profiling: whole-transcriptome RNA-sequencing is the most informative modality and now routinely detects USP6 fusions and identifies novel partners (PMID: 41432301; PMID: 41293881).

7. Anatomical Structures Affected

  • Organ / system level: skeletal system (musculoskeletal). Primary structure = bone (UBERON:0002481, bone tissue; UBERON:0001474, bone element). Secondary involvement by mass effect: spinal cord/nerve roots (spinal ABC), orbit/eye (orbital ABC), paranasal sinuses and jaw (craniofacial ABC).
  • Common sites: metaphysis of long bones — especially about the knee (distal femur UBERON:0002862, proximal tibia); also humerus, pelvis, and posterior elements of vertebrae (UBERON:0002412) (PMID: 22474093; PMID: 35941207).
  • Uncommon sites: mandible/maxilla (PMID: 18761766; PMID: 16609883), orbit (PMID: 36356178), skull base, and other flat/craniofacial bones (often solid variant).
  • Tissue level: connective tissue / bone; fibrous septa with myofibroblasts. Subcellular (GO CC): cytoplasm (GO:0005737), nucleus (GO:0005634, site of NF-κB action); extracellular region/matrix (GO:0005576) for secreted MMPs.
  • Localization / lateralization: usually solitary and unilateral / monostotic; rare polyostotic and synchronous presentations are reported (e.g., multi-vertebral solid variant, PMID: 35717456).

8. Temporal Development

  • Onset: predominantly pediatric/adolescent (first two decades); can occur in young adults. Onset is typically subacute to chronic with progressive pain and swelling; occasionally acute presentation via pathologic fracture (PMID: 22474093).
  • Progression: locally aggressive and often rapidly expansile, but benign (non-metastasizing). No formal malignant staging applies.
  • Disease course: effectively curable with adequate local control; the natural risk is local recurrence, usually within 2 years (PMID: 36356178).
  • Remission: achieved by treatment (surgery, sclerotherapy, denosumab). Rare spontaneous regression is described but not the norm. Critical window: recurrence surveillance is most important in the first 2 years post-treatment.

9. Inheritance and Population

  • Epidemiology: ABC is rare, comprising roughly 1–2% of primary bone tumors; commonly cited incidence is on the order of ~0.1–0.15 per 100,000/year. Peak incidence in the first two decades of life (PMID: 22474093; PMID: 35941207).
  • Inheritance: not inherited. The driver is a somatic USP6 rearrangement; there is no Mendelian inheritance pattern, no penetrance/expressivity, no anticipation, no founder effect, and no carrier frequency to report.
  • Sex ratio: approximately equal, with a slight female predominance in some series.
  • Age distribution: heavily skewed toward children and adolescents.
  • Geographic distribution: no defined endemic distribution; occurs worldwide.

10. Diagnostics

Imaging. Radiography shows an eccentric, expansile, radiolucent (lytic) metaphyseal lesion with cortical thinning. MRI classically demonstrates fluid-fluid levels from layering of blood components — a hallmark but not pathognomonic feature (also seen in telangiectatic osteosarcoma). CT delineates cortical integrity (PMID: 22474093; PMID: 30413280). RadLex/Radiopaedia are relevant imaging references.

Histopathology / biopsy. Blood-filled cystic spaces separated by fibrous septa containing bland spindle (myofibroblastic) cells, osteoclast-like multinucleated giant cells, and reactive woven bone; myofibroblastic cells are smooth-muscle-actin (SMA) positive (PMID: 41432301). The solid variant lacks prominent cystic spaces and can closely mimic other tumors (PMID: 30413280; PMID: 35102523).

Molecular (definitive). USP6 FISH (break-apart) and targeted RNA-sequencing / NGS detect the USP6 rearrangement and confirm primary ABC, distinguishing it from secondary ABC-like change and from mimics. RNA-seq is especially valuable in solid variants and unusual locations where FISH may miss atypical fusions (PMID: 15509545; PMID: 35102523; PMID: 41432301). Nanopore/long-read DNA sequencing can resolve complex rearrangements (e.g., chromothripsis-generated fusions) (PMID: 38979775).

Differential diagnosis. Telangiectatic osteosarcoma (critical malignant mimic), giant cell tumor of bone, unicameral (simple) bone cyst, chondroblastoma with ABC-like change, fibrous dysplasia, osteoblastoma; solid-variant ABC additionally mimics Ewing sarcoma, Langerhans cell histiocytosis, and metastasis. USP6 status is the key molecular discriminator for primary ABC (PMID: 35102523; PMID: 22474093).

Screening: none — ABC is somatic, non-heritable, and sporadic; population/genetic screening is not applicable.

11. Outcome / Prognosis

  • Survival / mortality: ABC is benign and does not metastasize; disease-specific mortality is negligible. Life expectancy is normal.
  • Morbidity: driven by local destruction — pain, pathologic fracture, growth disturbance (when the physis/triradiate cartilage is involved), and neurologic/ophthalmic deficits at spinal/orbital sites. With modern treatment, functional outcomes are generally excellent (TESS 95, MSTS 93% in pediatric pelvic ABC; PMID: 24817630).
  • Principal adverse outcome — recurrence: ~25–31% after simple curettage, reduced with adjuvants or sclerotherapy (see Finding 3). Recurrences usually manifest within 2 years (PMID: 37638388; PMID: 36356178).
  • Prognostic factors: anatomic site (spine, pelvis, juxta-articular = higher morbidity and technical difficulty), completeness of local control/resection, and lesion size. Molecular prognostic biomarkers beyond the diagnostic USP6 fusion are not established.

12. Treatment

Surgical / interventional (mainstay). - Intralesional curettage ± bone grafting — standard of care; recurrence ~25–31% (PMID: 37638388). NCIT: Curettage; Bone Graft. - Extended/adjuvant curettage — high-speed burr, electrocautery, phenol, cryotherapy reduce recurrence (e.g., 4-step spinal technique: 19% vs 50%; PMID: 32986586; pediatric pelvic extended curettage with excellent outcomes, PMID: 24817630; femoral head/neck salvage, PMID: 29416170). - En bloc resection / reconstruction — for aggressive or recurrent lesions; Ilizarov bone transport for large defects (PMID: 39600861); avascular/vascular bone grafting (PMID: 28463677). - Selective arterial embolization — as adjunct or primary therapy, especially for hypervascular spinal lesions (PMID: 37638388).

Minimally invasive / percutaneous. - Image-guided doxycycline sclerotherapy — 99% ultimate success, 16% recurrence resolved with repeat treatment; effective for appendicular, pelvic, mandibular, and recurrent lesions (PMID: 39265785; PMID: 39311568; PMID: 39637081). CHEBI: doxycycline (CHEBI:50845). - Percutaneous cryoablation ± protective doxycycline sclerotherapy — for lesions near critical neurovascular structures (PMID: 38567007). - Modified single-session sclerograft (doxycycline ± cryoablation + regenerative grafting) — 25.9% reintervention (PMID: 42477120). - Osteoconductive cement injection (e.g., Cerament) for select spinal lesions (PMID: 24186854).

Pharmacotherapy / targeted (mechanism-based). - Denosumab — human monoclonal anti-RANKL antibody. Targets the RANK/RANKL osteoclast axis implicated in ABC bone destruction. Produces symptomatic relief, calcification, size reduction, and devascularization; used as rescue therapy for recurrent/unresectable disease and as neoadjuvant to enable safer resection of spinal ABC (PMID: 26730528; PMID: 36282899; PMID: 27244112; scoping review PMID: 39445490). NCIT: Denosumab (C2724). Caution: rebound and long-term efficacy after cessation remain under study.

"The bone destruction in both giant cell tumors of bone and ABCs is mediated by RANK ligand (RANKL) produced by the tumor cells. Denosumab, a human monoclonal antibody to RANKL, is effective in the treatment of giant cell tumors of bone." — PMID: 26730528

Treatment strategy. Choice depends on site, size, and aggressiveness. Long-bone/appendicular lesions: curettage + adjuvant or doxycycline sclerotherapy. Spinal/sacral/pelvic lesions: embolization, extended curettage, and/or neoadjuvant denosumab to reduce vascularity and morbidity. Orbital/craniofacial: surgery, embolization, and RANKL inhibition (PMID: 36356178).

13. Prevention

No primary prevention exists — ABC arises from a sporadic somatic rearrangement with no known modifiable risk factors and no infectious or hereditary basis. Secondary/tertiary prevention focuses on early diagnosis and complete local control to prevent recurrence and complications: aggressive adjuvant curettage, sclerotherapy, and post-treatment imaging surveillance (particularly within 2 years). Genetic counseling, carrier/prenatal screening, immunization, and public-health interventions are not applicable.

14. Other Species / Natural Disease

  • Taxonomy / natural disease: Aneurysmal bone cysts occur naturally in domestic animals (notably horses, Equus caballus, NCBI Taxon 9796; and dogs, Canis lupus familiaris, NCBI Taxon 9615), where they present as expansile, blood-filled osteolytic bone lesions analogous to the human disease (veterinary/OMIA literature). Detailed molecular (USP6) characterization in animals is limited.
  • Orthology: USP6 is notable as a primate-specific/hominoid gene that arose via a chimeric duplication event; a true one-to-one rodent ortholog is lacking, which constrains conventional mouse modeling (see Section 15).
  • Zoonosis: not applicable — ABC is neoplastic, not transmissible.

15. Model Organisms

  • Xenograft / cell models (primary evidence): Overexpression of TRE17/USP6 in cultured cells and xenograft tumors recapitulates key ABC features — vascularized, matrix-degrading tumor formation dependent on the USP catalytic domain and NF-κB activation (PMID: 20418905). This in vitro/xenograft system is the principal functional model of ABC pathogenesis.
  • Genetic engineering: transgenic/inducible USP6-overexpression constructs are used to study downstream signaling (NF-κB, MMP-9/10, RhoA-ROCK).
  • Limitation: because USP6 is essentially primate-specific and acts through a promoter-swap overexpression mechanism, standard rodent knockout models do not naturally reproduce the disease; models rely on forced human USP6 overexpression rather than endogenous orthologous mutation. This is a recognized gap.
  • Applications: these models establish causality of the USP6→NF-κB→MMP axis and provide a platform to test USP6-deubiquitinase inhibitors, NF-κB inhibitors, and RANKL-targeted agents.

Mechanistic Model / Interpretation

  Somatic 17p13.2 rearrangement (promoter swap)
  e.g. CDH11 / MYH9 / FAT1 / AHNAK / PAFAH1B1 / FGFR1 promoter  ──►  USP6 (full-length)
        │  (in myofibroblastic SPINDLE cell only — the neoplastic cell)
        ▼
     USP6 overexpression  (gain of function; requires deubiquitinase/USP activity)
        │
     ┌──────────┴───────────┐
     ▼                      ▼
     RhoA / ROCK              NF-κB activation
     └──────────┬───────────┘
        ▼
Transcription of MMP-9 / MMP-10  +  pro-angiogenic signaling
        │
        ▼
   ECM degradation → blood-filled cystic vascular spaces (aneurysmal architecture)
        │
        ▼
     Lesional RANKL production  ──►  recruitment/activation of osteoclast-like GIANT CELLS
        │                         │
        ▼                         ▼
      Osteoclastic bone resorption → OSTEOLYSIS, cortical expansion/thinning
        │
        ▼
   CLINICAL: pain, swelling, pathologic fracture, neurologic/ophthalmic compromise

      Targeted intervention points:
• RANKL  ──► DENOSUMAB (blocks osteoclast axis; devascularization/calcification)
• Cyst cavity ──► DOXYCYCLINE sclerotherapy (also an MMP inhibitor) / cryoablation
• Whole lesion ──► curettage + adjuvants / embolization / resection

Two features of this model are worth emphasizing for a knowledge base. First, the single-cell specificity of the driver — USP6 rearrangement occurs only in the myofibroblastic spindle cell — reframes the giant cells and vascular spaces as reactive, recruited components downstream of a myofibroblast-intrinsic oncogenic program. Second, the model unifies diagnosis and therapy: the same USP6 lesion that defines primary ABC molecularly (FISH/RNA-seq) sits upstream of the RANKL axis that denosumab targets and the MMP/matrix program that doxycycline sclerotherapy disrupts (doxycycline is itself a known MMP inhibitor, an appealing mechanistic congruence).

Evidence Base

PMID Title (abbrev.) Contribution
15509545 USP6/CDH11 identify the neoplastic cell in primary ABC Foundational — clonal 17p13 fusion in 69% of primary ABCs; restricted to spindle cells; absent in secondary ABC. Establishes neoplastic nature and cell of origin.
20418905 TRE17/USP6 induces MMPs via NF-κB Foundational mechanism — USP6 (USP-activity-dependent) activates NF-κB via RhoA/ROCK to induce MMP-9/10; xenografts reproduce ABC.
35941207 Update on ABC: pathophysiology, imaging, treatment Modern review; 70/30 primary/secondary split; clinical and radiologic synthesis.
41293881 Morphomolecular study of 175 USP6-associated neoplasms Fusion-partner diversity (22 novel); partner depends on morphology/location.
41432301 3 ABCs with novel USP6 partners SEC24D/HNRNPC/ERRFI1::USP6; all upregulate full-length USP6; SMA+ myofibroblasts.
35102523 Solid-variant craniofacial ABC FAT1/MIR22HG::USP6; NGS superior to FISH for atypical fusions.
38979775 Chromothripsis-induced PAFAH1B1::USP6 Complex rearrangement; solid ABC mimicking osteosarcoma; long-read sequencing.
26730528 Response of ABC to denosumab RANKL-driven osteolysis; denosumab yields new bone, loss of giant cells.
36282899 Neoadjuvant denosumab Calcification/devascularization enabling safer spinal resection.
27244112 Denosumab for spinal GCT/ABC Anti-RANKL reduces tumor size and enables surgery.
37638388 Embolization vs curettage Baseline curettage recurrence ~25–31%.
39265785 Doxycycline sclerotherapy, 14-yr experience 99% success; 16% recurrence resolved with repeat doxycycline.
32986586 4-step technique, pediatric spinal ABC Adjuvant curettage cuts recurrence 50%→19%.
42477120 Modified sclerograft Single-session; 25.9% reintervention.
24817630 Pelvic ABC QoL Excellent long-term function (TESS 95, MSTS 93%, SF-36 87%).
22474093 Aneurysmal bone cyst (review) Clinical/radiologic overview; differential diagnosis; fluid-fluid levels.

Evidence source types: human clinical/pathology series (majority); in vitro + xenograft functional biology (PMID: 20418905); molecular cytogenetics (PMID: 15509545) and NGS/RNA-seq case series.

Limitations and Knowledge Gaps

  1. No native animal genetic model. USP6 is primate/hominoid-specific, so there is no straightforward orthologous rodent knock-in; mechanistic data derive from human-USP6 overexpression and xenografts rather than an endogenous-mutation animal model.
  2. RANKL step is inferred, not fully proven in ABC. The osteoclast/RANKL branch is strongly supported by denosumab response and analogy to giant cell tumor, but a direct, quantitative demonstration that USP6-driven myofibroblasts produce RANKL to recruit ABC giant cells is less rigorously established than the upstream USP6→NF-κB→MMP steps.
  3. Denosumab durability unknown. Reported responses are largely from case reports/small series; rebound after discontinuation, optimal duration, and long-term recurrence are not well quantified.
  4. Secondary ABC pathophysiology. The ~30% of ABC-like lesions lack USP6 and are mechanistically heterogeneous (driven by the host lesion); their biology is under-characterized in this report.
  5. Epidemiology precision. Prevalence/incidence figures are approximate; ABC is rare and under-registered, and no large population registry estimate was independently derived here.
  6. Fusion-partner functional consequences. Whether different partners (beyond driving overexpression) confer distinct clinical behavior (e.g., solid variant, site, recurrence) is an open question raised by the partner-diversity literature.
  7. Genotype–phenotype/prognostic biomarkers. Beyond the diagnostic USP6 fusion, no validated molecular prognostic markers stratify recurrence risk.

Proposed Follow-up Experiments / Actions

  1. Quantify RANKL in USP6-driven ABC — measure RANKL/OPG expression in laser-capture-microdissected spindle cells vs giant cells to close the inferential gap in the osteoclast branch; correlate with denosumab response.
  2. Prospective denosumab trial with defined stopping rules — track rebound, radiographic recurrence, and time-to-recurrence after cessation across anatomic sites, especially spine/sacrum.
  3. Partner-stratified outcome study — pool RNA-seq-characterized ABCs to test whether specific USP6 partners (e.g., FGFR1, AHNAK, chromothriptic fusions) associate with solid variant, atypical sites, or recurrence risk.
  4. Head-to-head modality comparison — prospective/registry comparison of doxycycline sclerotherapy vs adjuvant curettage vs denosumab for matched lesions, with recurrence and QoL (TESS/MSTS/SF-36) endpoints.
  5. Target the USP6 deubiquitinase — screen USP6 catalytic-domain inhibitors in the TRE17 xenograft model, exploiting the demonstrated dependence of tumorigenesis on USP activity.
  6. Standardize molecular diagnostics — adopt reflex RNA-seq (not FISH alone) for solid-variant and atypically located lesions to capture non-classical fusions and avoid misdiagnosis as osteosarcoma.
  7. Build a longitudinal ABC registry to firm up incidence, sex ratio, site distribution, and recurrence timelines with modern molecular confirmation.

Report compiled from molecular cytogenetic, functional, and clinical literature (33 papers reviewed; 3 confirmed findings). Evidence is predominantly human clinical/pathological with supporting in vitro/xenograft functional data. ABC is benign and non-metastatic; the dominant clinical concern is local recurrence, and the unifying biology is somatic USP6 overexpression driving an NF-κB/MMP/RANKL osteolytic program in myofibroblastic spindle cells.

Artifacts

Citations

  1. PMID:15509545
  2. PMID:35941207
  3. PMID:41293881
  4. PMID:35102523
  5. PMID:35717456
  6. PMID:38979775
  7. PMID:36356178
  8. PMID:41432301
  9. PMID:20418905
  10. PMID:37638388
  11. PMID:39265785
  12. PMID:42477120
  13. PMID:32986586
  14. PMID:22474093
  15. PMID:18761766
  16. PMID:24817630
  17. PMID:26730528
  18. PMID:36282899
  19. PMID:16609883
  20. PMID:30413280
  21. PMID:29416170
  22. PMID:39600861
  23. PMID:28463677
  24. PMID:39311568
  25. PMID:39637081
  26. PMID:38567007
  27. PMID:24186854
  28. PMID:27244112
  29. PMID:39445490